var title_f13_17_13584="12-lead ECG midseptal WPW";
var content_f13_17_13584=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    12-lead electrocardiogram (ECG) of a midseptal accessory AV pathway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram from a patient with Wolff-Parkinson-White syndrome. The ECG criteria for a midseptal pathway are intermediate between those for posteroseptal and anteroseptal connections within the triangle of Koch. These pathways have been difficult to predict from the surface ECG and have usually been grouped as septal pathways. The ECG shows positive delta waves in the lateral leads I, aVL, and V6, with early transition and a tall R wave in lead V2. The delta wave is positive in leads II and aVF and negative in lead III, and the QRS axis is &lt;0&deg;, localizing the pathway in the midseptum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_17_13584=[""].join("\n");
var outline_f13_17_13584=null;
var title_f13_17_13585="RA AC joint erosion x-ray";
var content_f13_17_13585=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F85835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F85835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Plain radiograph of &nbsp;acromioclavicular joint erosion in rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 437px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The AP projection of the left clavicle shows erosion of the undersurface of the distal clavicle (white arrow) at the acromioclavicular joint characteristic of rheumatoid arthritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Waite, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_17_13585=[""].join("\n");
var outline_f13_17_13585=null;
var title_f13_17_13586="Interactive diabetes case 5: Insulin management in a 73-year-old diabetic woman admitted to the hospital";
var content_f13_17_13586=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Interactive diabetes case 5: Insulin management in a 73-year-old diabetic woman admitted to the hospital",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/17/13586/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/17/13586/contributors\">",
"     Lloyd Axelrod, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/17/13586/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/17/13586/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/17/13586/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/17/13586/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/17/13586/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;You are asked to see a 73-year-old diabetic woman who was admitted to the hospital for a non-healing ulcer of the left great toe.",
"   </p>",
"   <p>",
"    The patient has a 36-year history of diabetes mellitus. At home, she takes NPH insulin 22 units before breakfast and 6 units at bedtime and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    6 units before dinner. She checks her blood glucose values three to four times a day. The results are as follows: those before breakfast are usually in the 90 to 150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5 to 8.3",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    range, those before lunch (checked infrequently) are in the 130 to 170",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.2 to 9.4",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    range, those before dinner are in the 100 to 150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.6 to 8.3",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    range, and those at bedtime are in the 140 to 180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.8 to 10",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    range. Her most recent A1C value was 7.8 percent three weeks ago. She follows the same ADA 1600 calorie diet that she has followed for the last 20 years. The weight is 155 pounds, height 5' 3\", BMI 27.5. She is on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    10 mg every morning and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    325 mg a day. She will get nothing by mouth the day following admission because she is scheduled for an arteriogram. The admitting physician holds the NPH insulin and puts the patient on an insulin sliding scale before meals and at bedtime, shown in the table (",
"    <a class=\"graphic graphic_table graphicRef65550 \" href=\"UTD.htm?4/41/4763\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The patient also receives IV fluids with D5W at 80",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    starting at 6 am on the first full hospital day. The patient's diabetes medication history reveals the following, shown in the table (",
"    <a class=\"graphic graphic_table graphicRef74639 \" href=\"UTD.htm?13/34/13868\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The patient resumes her meals on December 3 at dinner, following the same diet as at home. The serum creatinine remains normal following the arteriogram. The patient is angry and tearful because she feels her diabetes has \"gone crazy.\" She wants to resume the insulin regimen she uses at home and go home, where she will be safer. The physician is reluctant to return to the patient's previous regimen, fearing that the NPH insulin will cause further episodes of hypoglycemia. You are asked to assist with diabetes management. The case manager wants to know whether the patient can be sent home today.",
"   </p>",
"   <p>",
"    What is your assessment and plan?",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient has unexplained labile diabetes. You suspect that there is osteomyelitis of the left great toe, and that this lesion is intermittently releasing cytokines into the circulation, creating intermittent insulin resistance and hyperglycemia. You recommend an insulin infusion to provide maximum flexibility, transfer to the medical intensive care unit and consultation with an infectious disease specialist. (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?13/17/13586-a1?source=see_link\">",
"       \"Interactive diabetes case 5: Insulin management in a 73-year-old diabetic woman admitted to the hospital - A1\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The default sliding scale ordered on admission is inappropriate for this patient, who appears to need larger doses in the morning and smaller doses at bedtime. You recommend that separate sliding scales be used at different times of day, giving more insulin at all levels of blood glucose before meals, and less insulin at all levels of blood glucose at bedtime. You defer discharge to assess the patient's response to the new regimen. (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?13/17/13586-a2?source=see_link\">",
"       \"Interactive diabetes case 5: Insulin management in a 73-year-old diabetic woman admitted to the hospital - A2\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      You suspect that the patient has type 1 diabetes despite her age. You attribute the lability of blood glucose values to sole reliance on an insulin sliding scale without any basal intermediate- or long-acting insulin in a patient with type 1 diabetes. You agree with the patient that she needs to return to the insulin regimen she uses at home, starting the same day (December 5) at dinner time. You suggest that the patient may be ready for discharge the following day, but you wish to assess the patient's response to her insulin regimen the following day before discharge. (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?13/17/13586-a3?source=see_link\">",
"       \"Interactive diabetes case 5: Insulin management in a 73-year-old diabetic woman admitted to the hospital - A3\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      You suspect that the patient has type 1 diabetes despite her age. You attribute the lability of blood glucose values to sole reliance on an insulin sliding scale without any basal intermediate- or long-acting insulin in a patient with type 1 diabetes. However, you are concerned by the recurrent episodes of hypoglycemia, and advise that the patient receive only half of her usual doses of NPH insulin along with the sliding scale of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"       regular insulin",
"      </a>",
"      . You suggest that the patient may be ready for discharge the following day, but you wish to assess the patient's response to her insulin regimen the following day before discharge. (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?13/17/13586-a4?source=see_link\">",
"       \"Interactive diabetes case 5: Insulin management in a 73-year-old diabetic woman admitted to the hospital - A4\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4116 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-6C4A3AC97D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_17_13586=[""].join("\n");
var outline_f13_17_13586=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CASE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/4116\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/4116|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/41/4763\" title=\"table 1\">",
"      Insulin sliding scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/34/13868\" title=\"table 2\">",
"      Patient diabetes medication history",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?13/17/13586-a1?source=related_link\">",
"      Interactive diabetes case 5: Insulin management in a 73-year-old diabetic woman admitted to the hospital - A1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?13/17/13586-a2?source=related_link\">",
"      Interactive diabetes case 5: Insulin management in a 73-year-old diabetic woman admitted to the hospital - A2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?13/17/13586-a3?source=related_link\">",
"      Interactive diabetes case 5: Insulin management in a 73-year-old diabetic woman admitted to the hospital - A3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?13/17/13586-a4?source=related_link\">",
"      Interactive diabetes case 5: Insulin management in a 73-year-old diabetic woman admitted to the hospital - A4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_17_13587="Straddle injury2";
var content_f13_17_13587=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prepubertal child with laceration from straddle injury, after cleaning",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note bleeding out of proportion to size of laceration. Interrupted sutures were placed for hemostasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_17_13587=[""].join("\n");
var outline_f13_17_13587=null;
var title_f13_17_13588="Tinea versicolor chest";
var content_f13_17_13588=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78860&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78860&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tinea versicolor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple light brown coalescing macules are present on the chest.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_17_13588=[""].join("\n");
var outline_f13_17_13588=null;
var title_f13_17_13589="Calcium carbonate: Patient drug information";
var content_f13_17_13589=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Calcium carbonate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     see \"Calcium carbonate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/38/18024?source=see_link\">",
"     see \"Calcium carbonate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alcalak [OTC];",
"     </li>",
"     <li>",
"      Alka-Mints&reg; [OTC];",
"     </li>",
"     <li>",
"      Cal-Gest&reg; [OTC];",
"     </li>",
"     <li>",
"      Cal-Mint [OTC];",
"     </li>",
"     <li>",
"      Calci-Chew&reg; [OTC];",
"     </li>",
"     <li>",
"      Calci-Mix&reg; [OTC];",
"     </li>",
"     <li>",
"      Caltrate&reg; 600 [OTC];",
"     </li>",
"     <li>",
"      Children's Pepto [OTC];",
"     </li>",
"     <li>",
"      Chooz&reg; [OTC];",
"     </li>",
"     <li>",
"      Florical&reg; [OTC];",
"     </li>",
"     <li>",
"      Maalox&reg; Children's [OTC];",
"     </li>",
"     <li>",
"      Maalox&reg; Regular Strength [OTC];",
"     </li>",
"     <li>",
"      Nephro-Calci&reg; [OTC];",
"     </li>",
"     <li>",
"      Nutralox&reg; [OTC];",
"     </li>",
"     <li>",
"      Oysco 500 [OTC];",
"     </li>",
"     <li>",
"      Oystercal&trade; 500 [OTC];",
"     </li>",
"     <li>",
"      Rolaids&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Super Calcium 600 [OTC];",
"     </li>",
"     <li>",
"      Titralac&trade; [OTC];",
"     </li>",
"     <li>",
"      Tums&reg; E-X [OTC];",
"     </li>",
"     <li>",
"      Tums&reg; Extra Strength Sugar Free [OTC];",
"     </li>",
"     <li>",
"      Tums&reg; Quickpak [OTC];",
"     </li>",
"     <li>",
"      Tums&reg; Smoothies&trade; [OTC];",
"     </li>",
"     <li>",
"      Tums&reg; Ultra [OTC];",
"     </li>",
"     <li>",
"      Tums&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F144393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cal&reg;;",
"     </li>",
"     <li>",
"      Calcite-500;",
"     </li>",
"     <li>",
"      Caltrate&reg;;",
"     </li>",
"     <li>",
"      Caltrate&reg; Select;",
"     </li>",
"     <li>",
"      Os-Cal&reg;;",
"     </li>",
"     <li>",
"      Tums Extra Strength;",
"     </li>",
"     <li>",
"      Tums Smoothies;",
"     </li>",
"     <li>",
"      Tums&reg; Chews Extra Strength;",
"     </li>",
"     <li>",
"      Tums&reg; Regular Strength;",
"     </li>",
"     <li>",
"      Tums&reg; Ultra Strength",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12855556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help growth and good health.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691525",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to put off or treat soft, brittle bones (osteoporosis).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691408",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower high phosphate levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691873",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat heartburn and upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691428",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat low calcium levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701689",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to calcium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: High calcium levels, kidney stones, or low phosphate levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to tartrazine, talk with your doctor. Some products have tartrazine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Try to space other drugs from this one by 2 hours. This drug stops many drugs from getting into the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take iron, zinc, or folic acid within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695813",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 1 hour before or 2 hours after a high bran or fiber meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 1 to 3 hours after meals as an antacid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694604",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chewable tablet: Chew or crush well. Mix crushed tablet with food. Do not swallow it whole.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705494",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Soft, brittle bones (osteoporosis):",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11301 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-D2DE38DEA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_17_13589=[""].join("\n");
var outline_f13_17_13589=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144392\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144393\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12855556\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014172\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014171\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014176\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014177\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014179\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014174\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014175\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014180\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014181\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=related_link\">",
"      Calcium carbonate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/38/18024?source=related_link\">",
"      Calcium carbonate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_17_13590="Retinal vasculitis associated with primary ocular disorders";
var content_f13_17_13590=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Retinal vasculitis associated with primary ocular disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/17/13590/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/17/13590/contributors\">",
"     Michael Tolentino, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/17/13590/contributors\">",
"     Reza Dana, MD, MPH, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/17/13590/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/17/13590/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/17/13590/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/17/13590/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/17/13590/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/17/13590/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinal vasculitis is characterized by inflammation of the vessels of the retina [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13590/abstract/1\">",
"     1",
"    </a>",
"    ]. Positive findings on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    examination may be diagnostic, with fluorescein angiography demonstrating vascular leakage, perivascular staining, and capillary nonperfusion.",
"   </p>",
"   <p>",
"    The detection and characterization of retinal vasculitis may help in the diagnosis and management of a variety of disorders associated with ocular inflammation. These include systemic autoimmune disorders, some infectious diseases, and certain ocular processes.",
"   </p>",
"   <p>",
"    The clinical features of retinal vasculitis occurring in association with ocular disorders will be reviewed here. Retinal vasculitis due to systemic autoimmune disorders and infectious agents and a classification of the vasculitides are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33561?source=see_link\">",
"     \"Retinal vasculitis associated with systemic disorders and infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link\">",
"     \"Classification of and approach to the vasculitides in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic symptom of retinal vasculitis is a painless decrease in vision. Other symptoms may include a blind spot from ischemia-induced scotomas or floaters from vitritis. With macular involvement, patients may present with metamorphopsia (change in shape of an object) or abnormalities in color vision. Retinal vasculitis can also be asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities in the retinal vessels may be observed upon physical examination. Funduscopic findings include visible accumulation of inflammatory cells along vessel walls (vascular sheathing) (",
"    <a class=\"graphic graphic_picture graphicRef54347 \" href=\"UTD.htm?43/0/44046\">",
"     picture 1",
"    </a>",
"    ). The peripheral vessels are often more involved than central arterioles and venules, and there are frequently skip areas. With certain disorders such as sarcoidosis, lesions resembling candle-wax drippings or extensive perivascular inflammation may also be observed.",
"   </p>",
"   <p>",
"    The retinal vascular abnormalities are better demonstrated by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiography. One of the main changes on fluorescein angiography is perivascular staining, which reflects the increase in vascular permeability (",
"    <a class=\"graphic graphic_picture graphicRef66049 \" href=\"UTD.htm?22/56/23424\">",
"     picture 2",
"    </a>",
"    ). Cystoid macular edema and capillary nonperfusion also may be seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OCULAR SYNDROMES ASSOCIATED WITH RETINAL VASCULITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinal vasculitis can occur in association with four primary ocular inflammatory disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Idiopathic retinal vasculitis",
"     </li>",
"     <li>",
"      Pars planitis syndrome",
"     </li>",
"     <li>",
"      Birdshot retinochoroidopathy",
"     </li>",
"     <li>",
"      Eales&rsquo; disease (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Eales' disease'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Idiopathic retinal vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinal vasculitis may be the marker for or the harbinger of a systemic disease, usually a systemic inflammatory or immune disorder or an infectious disease, or may occur in isolation or as part of an ocular syndrome such as idiopathic retinal vasculitis aneurysm neuroretinitis (IRVAN). In a study of 150 patients initially diagnosed with isolated retinal vasculitis, 40 percent continued to have local disease at 10-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13590/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33561?source=see_link\">",
"     \"Retinal vasculitis associated with systemic disorders and infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequency of progression was substantially lower in a study performed by the National Eye Institute which evaluated 25 patients with primary retinal vasculitis, none of whom had evidence of an underlying causative systemic disorder at disease presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13590/abstract/3\">",
"     3",
"    </a>",
"    ]. At four-year follow-up, a systemic disease developed in only one patient (4 percent). As a result, if a thorough history, review of systems, and physical examination fail to uncover evidence of a systemic disease at disease presentation, the authors advise that the evaluation should generally be limited to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A complete blood count",
"     </li>",
"     <li>",
"      Urinalysis",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate",
"     </li>",
"     <li>",
"      Syphilis and HIV serologies",
"     </li>",
"     <li>",
"      Chest x-ray",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"       Fluorescein",
"      </a>",
"      angiography",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By comparison, a &ldquo;shotgun&rdquo; approach to laboratory testing can be expensive and often fruitless.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of idiopathic retinal vasculitis is usually reserved for those who develop poor vision. Systemic glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , and plasma exchange have all been used with variable efficacy, but none has been evaluated in a randomized fashion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13590/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. One retrospective study of 29 patients with vision threatening disease found that the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (initial dose 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) was associated with visual improvement in 60 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13590/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laser therapy is reserved for complications of retinal vasculitis, such as rubeosis iridis, recurrent vitreous hemorrhage, or retinal neovascularization. Other local procedures are warranted in selected patients. Vitrectomy has been indicated in dense vitreous inflammation, vitreous hemorrhage, retinal detachment, or epiretinal membrane formation. In some patients, filtering procedures (to increase drainage of aqueous) must be performed to treat the secondary glaucoma that may accompany retinal vasculitis and ocular inflammation. Secondary glaucoma can occur because of inflammation and or new blood vessel growth on the angle (drainage portion of the eye). In patients in whom macular edema develops,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    has been shown to reduce the edema and to improve vision [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13590/abstract/8\">",
"     8",
"    </a>",
"    ]. For IRVAN, a single systemic dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/40/33413?source=see_link\">",
"     ranibizumab",
"    </a>",
"    appears to be helpful in improving vision and in suppressing complications related to this rare form of retinal vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13590/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pars planitis syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pars planitis is a common ocular inflammatory condition (also called peripheral uveitis or intermediate uveitis) that is observed in young (typically female) adults and children; it represents one of the most common forms of uveitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13590/abstract/11\">",
"     11",
"    </a>",
"    ]. Although it occurs mostly in isolation and is hence termed idiopathic, a similar condition can be associated with multiple sclerosis and sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13590/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]; in one series, the incidence of progression to multiple sclerosis or optic neuritis was 20 percent at five years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13590/abstract/12\">",
"     12",
"    </a>",
"    ], although this rate of conversion is considered to be high based upon clinical experience. The term pars planitis is best reserved for idiopathic disease unrelated to systemic disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23817?source=see_link\">",
"     \"Uveitis: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major clinical findings of pars planitis are localized to the vitreous and posterior pole. One eye is usually affected more than the other, and the condition is bilateral in 80 percent of affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13590/abstract/13\">",
"     13",
"    </a>",
"    ]. The hallmark of the disorder is the presence of preretinal exudates over the inferior pars plana, findings referred to as snow banks. Patchy, peripheral retinal vasculitis often accompanies these lesions. In addition, the vitreous cavity usually has cells, debris, and snowball opacities.",
"   </p>",
"   <p>",
"    The two major causes of visual loss in pars planitis are macular edema and vitreous opacities. Cataracts are the most common complication and may result from inflammation and glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13590/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy consists of oral or",
"    <span class=\"nowrap\">",
"     intra/periocular",
"    </span>",
"    injected glucocorticoids. External cryotherapy has also been used directly on the snowbanks [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13590/abstract/15\">",
"     15",
"    </a>",
"    ]. If these modalities fail, systemic immunosuppression, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , has been used in isolated cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13590/abstract/5,16\">",
"     5,16",
"    </a>",
"    ]. Severe disease can often benefit from surgery to extract a cataract",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to remove vitreous debris.",
"   </p>",
"   <p>",
"    Decisions regarding the best modality and dose of therapy should be made in conjunction with an ophthalmologist expert in this area; as a general rule, immunosuppressive dosing is similar to that used in systemic vasculitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Birdshot retinochoroidopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Birdshot retinochoroidopathy is a rare ocular condition characterized by multiple discrete, cream-colored foci of depigmentation scattered throughout the fundus (",
"    <a class=\"graphic graphic_picture graphicRef70729 \" href=\"UTD.htm?8/5/8287\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13590/abstract/17\">",
"     17",
"    </a>",
"    ]. Involvement of the anterior segment is uncommon, although occasional cells and flares may be detected. There is usually cellular infiltration in the vitreous cavity. The diagnostic hallmark is the presence of vitreous cells, choroidal spots, and the absence of snowbanks or peripheral vascular change.",
"   </p>",
"   <p>",
"    Retinal vasculitis is also a common finding. In a study of 203 eyes with birdshot retinochoroidopathy, 40 percent had perivascular leakage and 62 percent had cystoid macular edema (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76872 \" href=\"UTD.htm?3/3/3120\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13590/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Birdshot retinochoroidopathy is strongly associated with the HLA-A29 haplotype [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13590/abstract/19\">",
"     19",
"    </a>",
"    ]. Because of this MHC association and its unique clinical features, it is possible to distinguish this disorder from other retinal vasculitides without a systemic workup.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of birdshot retinochoroidopathy is not uniformly successful; frequently, a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , and a third immunosuppressive agent is required for an optimal response. One study found that treatment regimens initially including low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    were more effective than treatment primarily with systemic glucocorticoid or without any systemic immunomodulatory therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13590/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of a sustained release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36192?source=see_link\">",
"     fluocinolone",
"    </a>",
"    implant has also shown promise; although ocular complications could be considerable, this method avoids systemic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13590/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Eales' disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eales&rsquo; disease is a retinal vasculopathy of the peripheral retina. Patients usually present with a decrease in vision, symptoms of floaters and cobwebs, and vitreous hemorrhage on funduscopic examination (",
"    <a class=\"graphic graphic_picture graphicRef50653 \" href=\"UTD.htm?2/31/2559\">",
"     picture 4",
"    </a>",
"    ). Although the disease is typically unilateral at onset, 80 to 90 percent eventually develop bilateral disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/15/16631?source=see_link\">",
"     \"Eales' disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Retinal vasculitis is the primary ocular manifestation of this condition. It is thought to affect retinal veins predominantly, but arteriolar involvement may also occur. Peripheral nonperfusion is commonly observed, and branch retinal vein occlusions may develop. Neovascularization is seen in up to 80 percent of affected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13590/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;No controlled scientific study has been performed to determine the optimal management of patients with Eales&rsquo; disease. We recommend the initial administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at a dose of 60",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Periocular glucocorticoid injections and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13590/abstract/23\">",
"     23",
"    </a>",
"    ] may also be useful in disease management.",
"   </p>",
"   <p>",
"    Most patients with Eales&rsquo; disease respond well to these medical interventions, and consideration of cytotoxic agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    is rarely required. Management of such cases requires close cooperation with retinal specialists.",
"   </p>",
"   <p>",
"    Laser photocoagulation is a useful modality for the treatment of neovascularization. If applied properly, it can help prevent the late complications of the disorder, including recurrent vitreous hemorrhage, retinal detachment, anterior segment neovascularization, and secondary glaucoma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13590/abstract/2\">",
"     2",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    has also been applied in Eales&rsquo; disease with good results for the treatment of neovascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13590/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10818133\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retinal vasculitis is characterized by inflammation of the vessels of the retina. The classic symptom of retinal vasculitis is a painless decrease in vision. Other symptoms may include a blind spot from ischemia-induced scotomas or floaters, metamorphopsia (change in shape of an object), and abnormalities in color vision. Retinal vasculitis can also be asymptomatic. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical characteristics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abnormalities in the retinal vessels may be observed upon physical examination. Funduscopic findings include visible accumulation of inflammatory cells along vessel walls (vascular sheathing) (",
"      <a class=\"graphic graphic_picture graphicRef54347 \" href=\"UTD.htm?43/0/44046\">",
"       picture 1",
"      </a>",
"      ). Positive findings on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      examination may be diagnostic, with fluorescein angiography demonstrating vascular leakage, perivascular staining, and capillary nonperfusion (",
"      <a class=\"graphic graphic_picture graphicRef66049 \" href=\"UTD.htm?22/56/23424\">",
"       picture 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Retinal vasculitis may be associated with a systemic disease or may occur in isolation, this latter form being more common. The primary ocular inflammatory disorders associated with retinal vasculitis include idiopathic retinal vasculitis, pars planitis syndrome, birdshot retinochoroidopathy, and Eales&rsquo; disease. Each exhibits characteristic and distinctive findings on ocular examination. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Ocular syndromes associated with retinal vasculitis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33561?source=see_link\">",
"       \"Retinal vasculitis associated with systemic disorders and infections\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H5\">",
"       'Idiopathic retinal vasculitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Pars planitis syndrome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Birdshot retinochoroidopathy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Eales' disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients in whom a thorough history, review of systems, and physical examination fail to uncover evidence of a systemic disease at disease presentation, the authors advise that the evaluation should generally be limited to a complete blood count, urinalysis, erythrocyte sedimentation rate, syphilis and HIV serologies, chest x-ray, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      angiography. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Idiopathic retinal vasculitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatments differ to some extent between disorders, but they usually involve systemic and sometimes",
"      <span class=\"nowrap\">",
"       intra/periocular",
"      </span>",
"      glucocorticoids and may include other immunosuppressive agents. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Idiopathic retinal vasculitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Pars planitis syndrome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Birdshot retinochoroidopathy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Eales' disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13590/abstract/1\">",
"      Stanford MR, Graham EM. Systemic associations of retinal vasculitis. Int Ophthalmol Clin 1991; 31:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13590/abstract/2\">",
"      Kasp E, Graham EM, Stanford MR, et al. A point prevalence study of 150 patients with idiopathic retinal vasculitis: 2. Clinical relevance of antiretinal autoimmunity and circulating immune complexes. Br J Ophthalmol 1989; 73:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13590/abstract/3\">",
"      George RK, Walton RC, Whitcup SM, Nussenblatt RB. Primary retinal vasculitis. Systemic associations and diagnostic evaluation. Ophthalmology 1996; 103:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13590/abstract/4\">",
"      Howe LJ, Stanford MR, Edelsten C, Graham EM. The efficacy of systemic corticosteroids in sight-threatening retinal vasculitis. Eye (Lond) 1994; 8 ( Pt 4):443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13590/abstract/5\">",
"      Nussenblatt RB, Palestine AG, Chan CC. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol 1983; 96:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13590/abstract/6\">",
"      Shah SS, Lowder CY, Schmitt MA, et al. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 1992; 99:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13590/abstract/7\">",
"      Wizemann AJ, Wizemann V. Therapeutic effects of short-term plasma exchange in endogenous uveitis. Am J Ophthalmol 1984; 97:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13590/abstract/8\">",
"      Moon SJ, Misch DM. Intravitreal Bevacizumab for Macular Edema from Idiopathic Retinal Vasculitis, Aneurysms, and Neuroretinitis. Ophthalmic Surg Lasers Imaging 2010; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13590/abstract/9\">",
"      Cheema RA, Al-Askar E, Cheema HR. Infliximab therapy for idiopathic retinal vasculitis, aneurysm, and neuroretinitis syndrome. J Ocul Pharmacol Ther 2011; 27:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13590/abstract/10\">",
"      Karagiannis D, Soumplis V, Georgalas I, Kandarakis A. Ranibizumab for idiopathic retinal vasculitis, aneurysms, and neuroretinitis: favorable results. Eur J Ophthalmol 2010; 20:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13590/abstract/11\">",
"      Henderly DE, Genstler AJ, Smith RE, Rao NA. Changing patterns of uveitis. Am J Ophthalmol 1987; 103:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13590/abstract/12\">",
"      Malinowski SM, Pulido JS, Folk JC. Long-term visual outcome and complications associated with pars planitis. Ophthalmology 1993; 100:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13590/abstract/13\">",
"      Smith RE, Godfrey WA, Kimura SJ. Chronic cyclitis. I. Course and visual prognosis. Trans Am Acad Ophthalmol Otolaryngol 1973; 77:OP760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13590/abstract/14\">",
"      Smith RE, Godfrey WA, Kimura SJ. Complications of chronic cyclitis. Am J Ophthalmol 1976; 82:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13590/abstract/15\">",
"      Aaberg TM, Cesarz TJ, Flickinger RR. Treatment of peripheral uveoretinitis by cryotherapy. Am J Ophthalmol 1973; 75:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13590/abstract/16\">",
"      Wong VG. Immunosuppressive therapy of ocular inflammatory diseases. Arch Ophthalmol 1969; 81:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13590/abstract/17\">",
"      Ryan SJ, Maumenee AE. Birdshot retinochoroidopathy. Am J Ophthalmol 1980; 89:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13590/abstract/18\">",
"      Priem HA, Oosterhuis JA. Birdshot chorioretinopathy: clinical characteristics and evolution. Br J Ophthalmol 1988; 72:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13590/abstract/19\">",
"      Feltkamp TE. Ophthalmological significance of HLA associated uveitis. Eye (Lond) 1990; 4 ( Pt 6):839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13590/abstract/20\">",
"      Rothova A, Ossewaarde-van Norel A, Los LI, Berendschot TT. Efficacy of low-dose methotrexate treatment in birdshot chorioretinopathy. Retina 2011; 31:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13590/abstract/21\">",
"      Rush RB, Goldstein DA, Callanan DG, et al. Outcomes of birdshot chorioretinopathy treated with an intravitreal sustained-release fluocinolone acetonide-containing device. Am J Ophthalmol 2011; 151:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13590/abstract/22\">",
"      Elliot AJ. 30-year observation of patients with Eale's disease. Am J Ophthalmol 1975; 80:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13590/abstract/23\">",
"      Bali T, Saxena S, Kumar D, Nath R. Response time and safety profile of pulsed oral methotrexate therapy in idiopathic retinal periphlebitis. Eur J Ophthalmol 2005; 15:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13590/abstract/24\">",
"      Patwardhan SD, Azad R, Shah BM, Sharma Y. Role of intravitreal bevacizumab in Eales disease with dense vitreous hemorrhage: a prospective randomized control study. Retina 2011; 31:866.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8231 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-199.231.185.123-90A40F4040-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_17_13590=[""].join("\n");
var outline_f13_17_13590=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10818133\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OCULAR SYNDROMES ASSOCIATED WITH RETINAL VASCULITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Idiopathic retinal vasculitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pars planitis syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Birdshot retinochoroidopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Eales' disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10818133\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/8231\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/8231|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/3/3120\" title=\"diagnostic image 1\">",
"      Angio birdshot retinochoroid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/8231|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/0/44046\" title=\"picture 1\">",
"      Perivascular sheathing retina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/56/23424\" title=\"picture 2\">",
"      Perivascular staining retina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/5/8287\" title=\"picture 3\">",
"      Birdshot retinochoroidopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/31/2559\" title=\"picture 4\">",
"      Vitreous bleed in Eales disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/15/16631?source=related_link\">",
"      Eales' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33561?source=related_link\">",
"      Retinal vasculitis associated with systemic disorders and infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23817?source=related_link\">",
"      Uveitis: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_17_13591="Nonpharmacologic and preventive therapies of rheumatoid arthritis";
var content_f13_17_13591=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nonpharmacologic and preventive therapies of rheumatoid arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/17/13591/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/17/13591/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/17/13591/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/17/13591/contributors\">",
"     Allan Gibofsky, MD, JD, FACP, FCLM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/17/13591/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/17/13591/contributors\">",
"     James R O'Dell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/17/13591/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/17/13591/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/17/13591/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite advances in pharmacologic therapy for rheumatoid arthritis (RA), many patients continue to experience some measure of ongoing disease activity and resultant disability. Although measures aimed at identifying early active disease and controlling inflammation are essential, the disease itself and the drugs used for treatment may contribute to increased risks of cardiovascular disease, bone loss, and serious infection. Many of these risks can be substantially reduced by a range of preventive interventions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/11/184?source=see_link\">",
"     \"Disease outcome and functional capacity in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A comprehensive management program for RA includes patient education, psychosocial interventions, appropriate use of rest, exercise, physical and occupational therapy, and nutritional and dietary counseling. The management program also includes interventions to reduce the risks of cardiovascular disease and osteoporosis, and immunizations to decrease the risk of infectious complications of immunosuppressive therapies.",
"   </p>",
"   <p>",
"    The nonpharmacologic and preventive therapies used in the management of RA are presented here. An overview of the management of RA, including the stages of the disease, assessment of disease activity and severity, and pharmacologic management, is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NONPHARMACOLOGIC AND PREVENTIVE THERAPIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Patient education and counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Education and counseling are important in the management of RA, a disorder in which therapy is continuous, occasionally limited in efficacy, and sometimes toxic [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13591/abstract/1\">",
"     1",
"    </a>",
"    ]. The clinician can provide information concerning the therapeutic roles of physical therapy, medications, and surgery. A longitudinal plan should be developed with each patient that addresses prognosis and options for treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13591/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Informed and sympathetic discussions concerning alternative, controversial, and unproven therapies are also important elements of patient education. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7513?source=see_link\">",
"     \"Complementary and alternative remedies in rheumatic disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients have misconceptions about the nature of arthritis and its cause. Correcting these may help establish a good long-term relationship between the clinician and patient. Cognitive behavioral therapies may also significantly reduce the patient's self-reported pain, functional disabilities, joint involvement, disease activity, and feelings of low self-esteem [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13591/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients need to be convinced that modern therapeutic regimens for the disease are effective for most patients in diminishing pain and swelling and in retarding (sometimes preventing) joint destruction. There is evidence that the course of disease activity in RA patients has become milder in more recent years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13591/abstract/5\">",
"     5",
"    </a>",
"    ] and much of the improvement, particularly in the rate of progression of joint damage, may be attributable to earlier and more widespread use of effective medications [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13591/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients should be encouraged to seek information and care from health care professionals other than their clinicians. As an example, formal patient education programs, mostly delivered by voluntary agencies such as the Arthritis Foundations, may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      General information",
"     </li>",
"     <li>",
"      Teaching skills for management of chronic illness",
"     </li>",
"     <li>",
"      Strategies for preserving joint function",
"     </li>",
"     <li>",
"      Training in biofeedback and the use of cognitive-behavioral and other psychotherapeutic techniques",
"     </li>",
"     <li>",
"      Enhanced social support",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Such programs have been shown to reduce pain, depression, and disability. They also allow patients to share in management decisions, thereby gaining some control over their illness [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13591/abstract/7\">",
"     7",
"    </a>",
"    ]. A year 2003 meta-analysis of 17 trials of arthritis self-management educational interventions for patients with RA or osteoarthritis found a clinically small, but statistically significant, beneficial effect on both pain and disability (effect size 0.12, 95% CI 0-0.24, and 0.07, CI 0-0.15) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13591/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A year 2004 systematic review of patient education in RA concluded that there is evidence for these benefits, at least in the short-term; however, evidence of long-term effects on outcomes is lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13591/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Rest",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since RA produces fatigue, the performance of many normal tasks may be difficult. Resting an inflamed joint as well as the entire body by taking a nap may, therefore, be beneficial; these rest periods can alternate with exercise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain and stiffness often lead patients to avoid using affected joints. This lack of use can result in loss of joint motion, contractures, and muscle atrophy, thereby decreasing joint stability and producing a further increase in fatigue. As a result, it is important that patients exercise regularly to prevent and reverse these potentially disabling problems.",
"   </p>",
"   <p>",
"    Range of motion exercises help preserve or restore joint motion. Exercises to increase muscle strength (such as isometric, isotonic, isokinetic), performed as infrequently as once or twice a week, improve function and do not worsen disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13591/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regular aerobic exercise (such as walking, swimming, cycling, and supervised cardiorespiratory aerobic conditioning) improves muscle function, joint stability, aerobic capacity, and physical performance over the short-term and can result in improved overall pain control and quality of life, without an increase in disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13591/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. Whether these benefits are maintained in the long term is unclear. Preliminary evidence suggests aerobic weightbearing exercise may help prevent glucocorticoid-associated osteoporosis in RA [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13591/abstract/15\">",
"     15",
"    </a>",
"    ], a benefit which strength training alone probably does not produce [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13591/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exercise programs should be prescribed by a physical therapist and tailored for each patient's disease severity, body build, and previous activity level. High-intensity weightbearing exercises may not be appropriate for patients with preexisting structural damage of lower extremity joints [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13591/abstract/16\">",
"     16",
"    </a>",
"    ]. Less intense or non-weightbearing exercises are alternatives for such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of physical therapy are pain relief, reduction of inflammation, and preservation of joint integrity and function. Physical therapy principally involves specific modalities targeted to problem areas, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The application of heat [",
"      <a class=\"abstract\" href=\"UTD.htm?13/17/13591/abstract/17\">",
"       17",
"      </a>",
"      ] or cold to relieve pain or stiffness",
"     </li>",
"     <li>",
"      Ultrasound to assuage tenosynovitis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/17/13591/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Passive and active exercises to improve and maintain range of motion of joints",
"     </li>",
"     <li>",
"      Dynamic exercise to improve aerobic capacity and strength [",
"      <a class=\"abstract\" href=\"UTD.htm?13/17/13591/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Rest and rest splinting to reduce pain and improve function",
"     </li>",
"     <li>",
"      Finger splinting to prevent deformity or improve hand function",
"     </li>",
"     <li>",
"      Relaxation techniques to relieve secondary muscle spasm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Referral to a podiatrist for provision of semirigid orthoses and supportive footwear is also helpful for those with involvement of the feet, especially for those with metatarsalgia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13591/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Occupational therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Goals of occupational therapy (OT) are similar to those of physical therapy, but occupational therapists focus on upper extremity activities and offer services to patients with RA that most often include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Education regarding joint protection and self care",
"     </li>",
"     <li>",
"      Provision of assistive devices and splints",
"     </li>",
"     <li>",
"      Instruction in use of assistive devices",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A systematic review of OT interventions provided for patients with RA, published in 2002, found limited evidence of efficacy that comprehensive OT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    patient education by a therapist had a beneficial effect on patient functional ability, while",
"    <span class=\"nowrap\">",
"     hand/wrist",
"    </span>",
"    splinting decreased pain [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13591/abstract/21\">",
"     21",
"    </a>",
"    ]. However, a subsequent randomized trial in employed RA patients at risk of work disability found significant benefit at six months in both functional and work outcomes from combining usual medical care with targeted, comprehensive OT, compared with usual care alone (without OT) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13591/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Nutrition and dietary therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active RA may be associated with anorexia and poor dietary intake. Attempts to overcome these difficulties should, therefore, be a part of the management of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13591/abstract/23\">",
"     23",
"    </a>",
"    ]. Many different dietary manipulations have been proposed as therapy in RA, but the majority is unproven. An exception to this may be that diets rich in fish oil or a diet to which eicosapentaenoic acid or docosahexaenoic acid is added may result in decreased arachidonic acid metabolites and cytokines, with a concurrent decrease in symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13591/abstract/24\">",
"     24",
"    </a>",
"    ].The obese patient should be encouraged to lose weight, as even mild excess weight increases the stress upon joints involved with synovitis, potentially hastening joint destruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bone protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid arthritis alone appears to cause a gradual loss of bone mineral density, even without the administration of glucocorticoids (",
"    <a class=\"graphic graphic_table graphicRef76445 \" href=\"UTD.htm?2/21/2395\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis\", section on 'Osteopenia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=see_link\">",
"     \"Osteoporotic fracture risk assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prolonged use of large doses of glucocorticoids promotes osteopenia, while improved mobility associated with chronic use of lower doses (eg, less than 7.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    ) may at least partially offset the adverse effects on bone mineral content. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis\", section on 'Effect of low-dose glucocorticoid therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the risks associated with glucocorticoid-induced bone loss, preventive measures are warranted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cardiovascular risk reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of an increased risk of coronary atherosclerosis and associated morbidity and mortality in patients with RA, efforts to modify risk factors such as cigarette smoking, hyperlipidemia, hypertension, and sedentary life style should accompany treatment directed at RA. Control of the inflammatory process also may contribute to cardiovascular protection, while there is some evidence that statin therapy improves inflammation in patients with RA. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31433?source=see_link\">",
"     \"Coronary artery disease in rheumatoid arthritis: Diagnostic and therapeutic implications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/35/566?source=see_link&amp;anchor=H2#H2\">",
"     \"Miscellaneous novel therapies in rheumatoid arthritis\", section on 'Statins'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5576?source=see_link\">",
"     \"Overview of primary prevention of coronary heart disease and stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Vaccinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving immunosuppressive drugs should NOT receive live vaccines. Use of killed virus or polysaccharide vaccines (eg, influenza and pneumococcal vaccines) is appropriate for RA patients, whose disease and antirheumatic drug treatment put them at higher risk for serious infection.",
"   </p>",
"   <p>",
"    The following vaccination recommendations were included in the 2008 ACR guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13591/abstract/3\">",
"     3",
"    </a>",
"    ] and are consistent with Centers for Disease Control and Prevention (CDC) recommendations for influenza and pneumococcal vaccination:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Influenza vaccine should be given to all RA patients who are going to be or are already treated with immunosuppressive drugs, regardless of when the drugs are initiated, unless the patient was vaccinated during the previous influenza season. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link&amp;anchor=H775052810#H775052810\">",
"       \"Seasonal influenza vaccination in adults\", section on 'Schedule'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"       \"Seasonal influenza vaccination in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pneumococcal vaccine should be given to all RA patients who are going to be or are already treated with immunosuppressive drugs, and a single revaccination is warranted if &ge;5 years have elapsed since the first vaccination (",
"      <a class=\"graphic graphic_table graphicRef86782 \" href=\"UTD.htm?11/48/12046\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"       \"Pneumococcal vaccination in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"       Hepatitis B vaccine",
"      </a>",
"      should be given before",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      , and biologic DMARDs, if risk factors for hepatitis B are present, such as a history of multiple sexual partners in past six months, household contacts with hepatitis B, intravenous drug abuse, or work in healthcare. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link\">",
"       \"Hepatitis B virus vaccination\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Low doses of glucocorticoids, disease modifying antirheumatic drugs, and tumor necrosis factor inhibitors may blunt, but do not appear to abolish, the response to such vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13591/abstract/25-27\">",
"     25-27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/22/9571?source=see_link\">",
"       \"Patient information: Arthritis and exercise (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=see_link\">",
"       \"Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=see_link\">",
"       \"Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28645?source=see_link\">",
"       \"Patient information: Arthritis and exercise (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H518884\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comprehensive management program for RA includes measures to prevent and treat disability resulting from the disease and to reduce other disease risks and the complications of immunosuppressive therapies. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Education and counseling are important in the management of RA. The clinician can provide information concerning the therapeutic roles of physical therapy, of medications, of surgery, and of complementary and alternative therapies. An individualized longitudinal plan should be developed with each patient that addresses prognosis and options for treatment. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Patient education and counseling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since RA produces fatigue, the performance of many normal tasks may be difficult. Resting an inflamed joint as well as the entire body by taking a nap may, therefore, be beneficial; these rest periods can alternate with exercise. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Rest'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pain and stiffness often lead patients to avoid using affected joints, which can result in loss of joint motion, contractures, and muscle atrophy, thereby decreasing joint stability and producing a further increase in fatigue. It is thus important that patients exercise regularly to prevent and reverse these potentially disabling problems. Such exercise may include a combination of range of motion exercises, muscle strengthening, and aerobic exercise. Exercise programs should be prescribed by a physical therapist and tailored for each patient. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Exercise'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goals of physical therapy are pain relief, reduction of inflammation, and preservation of joint integrity and function. Physical therapy involves specific modalities targeted to problem areas, Goals of occupational therapy (OT) are similar to those of physical therapy, but occupational therapists focus on upper extremity activities and offer services to patients with RA that most often include education regarding joint protection and self care, provision of assistive devices and splints, and instruction in their use. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Physical therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Occupational therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Active RA may be associated with anorexia and poor dietary intake. Attempts to overcome these difficulties should, therefore, be a part of the management of the disease. The obese patient should be encouraged to lose weight, as even mild excess weight increases the stress upon joints involved with synovitis, potentially hastening joint destruction. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Nutrition and dietary therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      RA itself, in addition to glucocorticoid use, can contribute to reductions in bone density and increase risk of osteoporosis. Appropriate preventive measures should be utilized. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Bone protection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of an increased risk of coronary atherosclerosis and associated morbidity and mortality in patients with RA, efforts to modify risk factors such as cigarette smoking, hyperlipidemia, hypertension, and sedentary life style should accompany treatment directed at RA. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Cardiovascular risk reduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients receiving immunosuppressive drugs should NOT receive live vaccines. Use of killed virus or polysaccharide vaccines (eg, influenza and pneumococcal vaccines) is appropriate for RA patients, whose disease and antirheumatic drug treatment put them at higher risk for serious infection. Vaccination recommendations are consistent with Centers for Disease Control and Prevention (CDC) recommendations for influenza and pneumococcal vaccination. Other vaccinations may also be indicated in specific patients at risk, including immunization for Hepatitis B. Low doses of glucocorticoids, disease modifying antirheumatic drugs, and tumor necrosis factor inhibitors may blunt, but do not appear to abolish, the response to such vaccines. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Vaccinations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13591/abstract/1\">",
"      Hawley DJ. Psycho-educational interventions in the treatment of arthritis. Baillieres Clin Rheumatol 1995; 9:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13591/abstract/2\">",
"      American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002; 46:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13591/abstract/3\">",
"      Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13591/abstract/4\">",
"      Bradley LA, Young LD, Anderson KO, et al. Effects of psychological therapy on pain behavior of rheumatoid arthritis patients. Treatment outcome and six-month followup. Arthritis Rheum 1987; 30:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13591/abstract/5\">",
"      Welsing PM, Fransen J, van Riel PL. Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis. Arthritis Rheum 2005; 52:2616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13591/abstract/6\">",
"      Finckh A, Choi HK, Wolfe F. Progression of radiographic joint damage in different eras: trends towards milder disease in rheumatoid arthritis are attributable to improved treatment. Ann Rheum Dis 2006; 65:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13591/abstract/7\">",
"      Lorig K. Patient education: treatment or nice extra. Br J Rheumatol 1995; 34:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13591/abstract/8\">",
"      Warsi A, LaValley MP, Wang PS, et al. Arthritis self-management education programs: a meta-analysis of the effect on pain and disability. Arthritis Rheum 2003; 48:2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13591/abstract/9\">",
"      Niedermann K, Fransen J, Knols R, Uebelhart D. Gap between short- and long-term effects of patient education in rheumatoid arthritis patients: a systematic review. Arthritis Rheum 2004; 51:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13591/abstract/10\">",
"      H&auml;kkinen A, Sokka T, Kotaniemi A, Hannonen P. A randomized two-year study of the effects of dynamic strength training on muscle strength, disease activity, functional capacity, and bone mineral density in early rheumatoid arthritis. Arthritis Rheum 2001; 44:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13591/abstract/11\">",
"      Stenstr&ouml;m CH. Therapeutic exercise in rheumatoid arthritis. Arthritis Care Res 1994; 7:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13591/abstract/12\">",
"      Van Den Ende CH, Vliet Vlieland TP, Munneke M, Hazes JM. Dynamic exercise therapy for rheumatoid arthritis. Cochrane Database Syst Rev 2000; :CD000322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13591/abstract/13\">",
"      de Jong Z, Munneke M, Zwinderman AH, et al. Is a long-term high-intensity exercise program effective and safe in patients with rheumatoid arthritis? Results of a randomized controlled trial. Arthritis Rheum 2003; 48:2415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13591/abstract/14\">",
"      Baillet A, Zeboulon N, Gossec L, et al. Efficacy of cardiorespiratory aerobic exercise in rheumatoid arthritis: meta-analysis of randomized controlled trials. Arthritis Care Res (Hoboken) 2010; 62:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13591/abstract/15\">",
"      Westby MD, Wade JP, Rangno KK, Berkowitz J. A randomized controlled trial to evaluate the effectiveness of an exercise program in women with rheumatoid arthritis taking low dose prednisone. J Rheumatol 2000; 27:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13591/abstract/16\">",
"      Munneke M, de Jong Z, Zwinderman AH, et al. Effect of a high-intensity weight-bearing exercise program on radiologic damage progression of the large joints in subgroups of patients with rheumatoid arthritis. Arthritis Rheum 2005; 53:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13591/abstract/17\">",
"      Robinson V, Brosseau L, Casimiro L, et al. Thermotherapy for treating rheumatoid arthritis. Cochrane Database Syst Rev 2002; :CD002826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13591/abstract/18\">",
"      Casimiro L, Brosseau L, Robinson V, et al. Therapeutic ultrasound for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2002; :CD003787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13591/abstract/19\">",
"      Hurkmans E, van der Giesen FJ, Vliet Vlieland TP, et al. Dynamic exercise programs (aerobic capacity and/or muscle strength training) in patients with rheumatoid arthritis. Cochrane Database Syst Rev 2009; :CD006853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13591/abstract/20\">",
"      Chalmers AC, Busby C, Goyert J, et al. Metatarsalgia and rheumatoid arthritis--a randomized, single blind, sequential trial comparing 2 types of foot orthoses and supportive shoes. J Rheumatol 2000; 27:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13591/abstract/21\">",
"      Steultjens EM, Dekker J, Bouter LM, et al. Occupational therapy for rheumatoid arthritis: a systematic review. Arthritis Rheum 2002; 47:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13591/abstract/22\">",
"      Macedo AM, Oakley SP, Panayi GS, Kirkham BW. Functional and work outcomes improve in patients with rheumatoid arthritis who receive targeted, comprehensive occupational therapy. Arthritis Rheum 2009; 61:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13591/abstract/23\">",
"      Cleland LG, Hill CL, James MJ. Diet and arthritis. Baillieres Clin Rheumatol 1995; 9:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13591/abstract/24\">",
"      Geusens P, Wouters C, Nijs J, et al. Long-term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis. A 12-month, double-blind, controlled study. Arthritis Rheum 1994; 37:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13591/abstract/25\">",
"      Fomin I, Caspi D, Levy V, et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 2006; 65:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13591/abstract/26\">",
"      Elkayam O, Paran D, Caspi D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 2002; 34:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13591/abstract/27\">",
"      Kapetanovic MC, Saxne T, Nilsson JA, Geborek P. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford) 2007; 46:608.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7498 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.80.101-E63CECF6F9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_17_13591=[""].join("\n");
var outline_f13_17_13591=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H518884\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NONPHARMACOLOGIC AND PREVENTIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Patient education and counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Rest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Occupational therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Nutrition and dietary therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bone protection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cardiovascular risk reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Vaccinations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H518884\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7498\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7498|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/21/2395\" title=\"table 1\">",
"      Risk factors for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/48/12046\" title=\"table 2\">",
"      Pneumococcal vaccination indications for adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7513?source=related_link\">",
"      Complementary and alternative remedies in rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31433?source=related_link\">",
"      Coronary artery disease in rheumatoid arthritis: Diagnostic and therapeutic implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/11/184?source=related_link\">",
"      Disease outcome and functional capacity in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/35/566?source=related_link\">",
"      Miscellaneous novel therapies in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=related_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5576?source=related_link\">",
"      Overview of primary prevention of coronary heart disease and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=related_link\">",
"      Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=related_link\">",
"      Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28645?source=related_link\">",
"      Patient information: Arthritis and exercise (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/22/9571?source=related_link\">",
"      Patient information: Arthritis and exercise (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=related_link\">",
"      Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=related_link\">",
"      Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=related_link\">",
"      Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=related_link\">",
"      Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_17_13592="Clinical evaluation of lower extremity chronic venous disease";
var content_f13_17_13592=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical evaluation of lower extremity chronic venous disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/17/13592/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/17/13592/contributors\">",
"     Patrick C Alguire, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/17/13592/contributors\">",
"     Barbara M Mathes, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/17/13592/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/17/13592/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/17/13592/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/17/13592/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/17/13592/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/17/13592/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic lower extremity venous disease is the most common vascular disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13592/abstract/1\">",
"     1",
"    </a>",
"    ]. Chronic venous disease refers to the presence of morphological (ie, venous dilation) or functional (eg, venous reflux) abnormalities of long duration and manifested by symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs indicating the need for further investigation or treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13592/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic venous disease encompasses the full spectrum of signs and symptoms associated with classes C&Oslash; to C6 of the Clinical-Etiology-Anatomy-Pathophysiology (CEAP) classification (",
"    <a class=\"graphic graphic_table graphicRef52388 \" href=\"UTD.htm?10/45/10973\">",
"     table 1",
"    </a>",
"    ), whereas the term \"chronic venous insufficiency\" is generally restricted to disease of greater severity (ie, classes C4 to C6) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13592/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, varicose veins in the absence of skin changes are not indicative of chronic venous insufficiency.",
"   </p>",
"   <p>",
"    Initial clinical presentation is highly variable with the most common symptoms consisting of lower extremity pain or discomfort. Physical findings include abnormal venous dilation (ie, telangiectasias, reticular veins, varicose veins), edema, inflammation, dermatitis, or ulceration. Chronic venous insufficiency is associated with chronic disability, diminished quality of life, and high health care costs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13592/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical evaluation of chronic venous disease is reviewed here. The classification, diagnostic evaluation and management of chronic venous disease are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11735?source=see_link\">",
"     \"Classification of lower extremity chronic venous disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=see_link\">",
"     \"Overview and management of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     APPROACH TO THE PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of chronic lower extremity venous disease is predominantly clinical. Initial evaluation consists of a thorough history and physical examination, with clinical classification of disease severity according to the Clinical-Etiology-Anatomy-Pathophysiology (CEAP) criteria (",
"    <a class=\"graphic graphic_table graphicRef52388 \" href=\"UTD.htm?10/45/10973\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13592/abstract/2\">",
"     2",
"    </a>",
"    ]. The CEAP classification is helpful in documenting venous disease severity both at initial presentation as well as in documenting changes over time. The CEAP clinical classification is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11735?source=see_link\">",
"     \"Classification of lower extremity chronic venous disorders\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H8\">",
"     'Clinical signs by CEAP category'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because the presence of dilated veins is a common incidental finding on routine physical examination, many individuals are already aware that they have a vein problem. Up to one half of patients, even some with very large varicosities, have no specific complaints [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13592/abstract/7\">",
"     7",
"    </a>",
"    ]. Symptomatic patients may or may not correlate certain lower extremity symptoms with the presence of abnormal veins; alternatively, the patient may erroneously attribute symptoms that are more consistent with orthopedic or arterial vascular disease to their visible veins.",
"   </p>",
"   <p>",
"    The major goal in the clinical diagnosis of lower extremity chronic venous disease is a full clinical assessment of the lower extremities with correct interpretation of the patient's complaints and correlation with physical signs. Inconsistencies between symptoms and clinical signs may require additional diagnostic evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors for venous disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is often very interested in knowing why he or she has developed a vein problem. To help the patient better understand his or her disorder, the patient should be questioned specifically for risk factors known to contribute to the development of chronic venous disease. The most common risk factors include advancing age, family history of venous disease, increased body mass index, smoking, a history of lower extremity trauma, prior venous thrombosis and, in women, pregnancy. A more complete review of risk factors is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview and management of lower extremity chronic venous disease\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Particular attention should be paid to identifying risk factors that can be modified (eg, obesity, lifestyle).",
"   </p>",
"   <p>",
"    The patient who has no identifiable risk factors may have suffered a remote lower extremity trauma they do not recall, or an undiagnosed deep vein thrombosis (DVT). Duplex ultrasound in these patients may identify valvular insufficiency, chronic vein wall thickening, or chronic thrombosis indicative of post-thrombotic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13592/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23127?source=see_link\">",
"     \"Post-thrombotic (postphlebitic) syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with more severe clinical manifestations (ie, edema, inflammation, ulcer) are typically older and may have significant associated medical conditions (eg, peripheral artery disease [PAD], heart failure, diabetes, arthritis).",
"   </p>",
"   <p>",
"    Chronic venous disease and arterial vascular disease have some common risk factors (eg, smoking, obesity) and pathophysiologic processes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13592/abstract/9\">",
"     9",
"    </a>",
"    ]. The presence of varicose veins has been associated with arterial disease in two studies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13592/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. One of these, a cross-sectional study, documented a 36 percent increase in the risk of developing coronary artery disease for men with varicose veins [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13592/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of these associations, a complete medical history with particular attention to cardiovascular disease and risk factors should be obtained since co-morbidities may impact diagnostic evaluation or management choices. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=see_link\">",
"     \"Overview and management of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;Health related quality of life outcome measures are increasingly being considered in the evaluation of the outcomes of treatment for chronic venous disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13592/abstract/12-17\">",
"     12-17",
"    </a>",
"    ]. Patients should be specifically questioned regarding the impact of symptoms on their daily activities, especially with respect to employment. The venous clinical severity score (VCSS) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?34/0/34818?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) and venous disability score (VDS) may aid with initial and follow up assessment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11735?source=see_link&amp;anchor=H31#H31\">",
"     \"Classification of lower extremity chronic venous disorders\", section on 'Measures of clinical severity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Individuals with varicose veins can have a lower perception of their general health compared to individuals without varicose veins, especially if clinical manifestations are more significant (eg, edema, skin changes) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13592/abstract/12\">",
"     12",
"    </a>",
"    ]. Quality of life measures improve with management of their superficial venous disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13592/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview and management of lower extremity chronic venous disease\", section on 'Management by CEAP clinical category'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with severe skin changes or venous ulceration also have reductions in quality of life measures that are further reduced coincident with the need for chronic wound management [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13592/abstract/16,17,19\">",
"     16,17,19",
"    </a>",
"    ]. Ulcer healing, however, may not always result in perceived improvements in quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13592/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=see_link&amp;anchor=H28#H28\">",
"     \"Medical management of lower extremity chronic venous disease\", section on 'Ulcer care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of symptoms varies widely. The onset of these symptoms relative to the appearance of visibly dilated veins, skin changes, or ulceration should be ascertained and correlated with any positive risk factors. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Risk factors for venous disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The most common symptoms reported by patients with chronic venous disease are limb discomfort (ie, tired, heavy legs), pain, and limb swelling. Pain and limb discomfort were reported as a significant symptom for each of the six CEAP clinical categories in at least 50 percent of individuals surveyed in one large cross sectional study [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13592/abstract/7\">",
"     7",
"    </a>",
"    ]. Pain may be generalized (ie, aching), or localized to specific veins, areas of lipodermatosclerosis, or ulceration. When pain accompanies more severe clinical manifestations, ambulation may become difficult or even impossible.",
"   </p>",
"   <p>",
"    Pain associated with venous disease is typically worse when standing, or when seated with the feet dependent for prolonged periods of time and improves with limb elevation and walking. These features distinguish chronic venous disease from typical symptoms associated with lower extremity occlusive peripheral artery disease. Patients with mild to moderate lower extremity PAD (ie, claudication) complain of pain with walking that is relieved by rest while those with more severe PAD may complain of more pain when the limb is elevated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=see_link\">",
"     \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pain associated with venous disease is typically directly associated with the affected veins, skin changes or ulceration; it does not radiate as with radiculopathies, and is not exacerbated by joint movement as in arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20810?source=see_link\">",
"     \"Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extremity swelling is reported by 25 to 75 percent of patients, and correlates with increasing clinical severity (ie, increasing CEAP category). Swelling is generally worse with prolonged standing and improves with leg elevation and walking. In women, exacerbation of symptoms can occur with the menses or pregnancy, due to increased fluid volume",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    higher circulating levels of estrogen.",
"   </p>",
"   <p>",
"    Other complaints include limb aching or generalized fatigue, skin discoloration or redness, muscle cramping, numbness, tingling, or itching. Numbness and tingling due to chronic venous disease can become chronic and may be difficult to distinguish from other causes of peripheral neuropathy that affect the lower extremity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13592/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31879?source=see_link&amp;anchor=H8#H8\">",
"     \"Approach to the patient with sensory loss\", section on 'Stocking-glove sensory loss'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients with chronic venous disease may seek medical attention for the first time due to chronic ulcers, or bleeding that can be spontaneous (varicose vein hemorrhage) or related to a wound [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13592/abstract/24\">",
"     24",
"    </a>",
"    ]. In one population survey of 600 patients, chronic ulceration was present for seven to nine months in 50 percent of patients and more than five years in 8 to 34 percent of patients at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13592/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients should be asked about the number and location of prior ulcerations, as well as the nature of any treatments used to aid in wound care. Studies based upon patient recall found that up to 67 to 75 percent of patients have recurrent ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13592/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PHYSICAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of physical assessment is to correlate the patient's symptoms with the clinical signs of venous disease. It is important to keep in mind that a subset of patients may have typical symptoms but no visible clinical signs, while other patients may have lower extremity symptoms that are not consistent with venous disease and more likely attributable to another process. Therefore, the patient should undergo a complete physical examination with a detailed lower extremity examination that includes assessment of clinical signs of venous disease, pulse examination, and neurologic assessment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link\">",
"     \"The detailed neurologic examination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The femoral and pedal pulses (ie, dorsalis pedis and posterior tibial pulses) are usually palpable in younger patients. In older patients, a hand held Doppler ultrasound may be necessary to assess pedal arterial flow. If there are any indications of arterial ischemia (ie, cool extremity, pulselessness, forefoot or digital ulceration), further noninvasive arterial evaluation should be undertaken. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14486?source=see_link\">",
"     \"Clinical manifestations and evaluation of chronic critical limb ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL SIGNS BY CEAP CATEGORY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     No clinical signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 20 percent of patients with clinical symptoms consistent with a chronic venous disorder have no visible clinical signs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13592/abstract/7\">",
"     7",
"    </a>",
"    ]. Duplex examination identifies functional disease (ie, venous reflux) in approximately 20 percent of these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview and management of lower extremity chronic venous disease\", section on 'Management by CEAP clinical category'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Telangiectasia/reticular veins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequently encountered manifestation of venous disease is mild venous dilation. Telangiectasias are a confluence of dilated intradermal venules less than one millimeter in diameter (",
"    <a class=\"graphic graphic_picture graphicRef62119 \" href=\"UTD.htm?17/58/18351\">",
"     picture 1",
"    </a>",
"    ). Telangiectasias are more common in women [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13592/abstract/7\">",
"     7",
"    </a>",
"    ]. Reticular veins are dilated, bluish subdermal veins, one to three millimeters in diameter, and are usually tortuous.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Varicose veins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicose veins are subcutaneous dilated, tortuous veins greater than three millimeters in diameter (",
"    <a class=\"graphic graphic_picture graphicRef68551 \" href=\"UTD.htm?39/36/40526\">",
"     picture 2",
"    </a>",
"    ). They may involve the saphenous veins, saphenous tributaries, or non-saphenous superficial leg veins (",
"    <a class=\"graphic graphic_figure graphicRef55019 graphicRef52340 \" href=\"UTD.htm?5/25/5527\">",
"     figure 1A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11735?source=see_link&amp;anchor=H21#H21\">",
"     \"Classification of lower extremity chronic venous disorders\", section on 'Anatomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Longstanding venous disease associated with venous reflux is characterized by the development of dependent ankle edema (",
"    <a class=\"graphic graphic_picture graphicRef70438 \" href=\"UTD.htm?33/60/34766\">",
"     picture 3",
"    </a>",
"    ) which may progress over time to include the calf region. In the early stages of chronic venous insufficiency, edema may be present only at the end of the day; however, with time it can become persistent throughout the day.",
"   </p>",
"   <p>",
"    The presence of edema is not a specific finding. It occurs when the hydrostatic pressure gradient is substantially increased (eg, congestive heart failure, renal failure, or locally with venous thrombosis or insufficiency), the oncotic pressure gradient is substantially reduced (marked hypoalbuminemia), vascular (capillary) permeability is increased, or lymphatic flow is obstructed (",
"    <a class=\"graphic graphic_table graphicRef53550 \" href=\"UTD.htm?5/3/5181\">",
"     table 2",
"    </a>",
"    ). Other etiologies may also lead to lower extremity edema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/34/36393?source=see_link\">",
"     \"Pathophysiology and etiology of edema in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=see_link\">",
"     \"Clinical manifestations and diagnosis of lymphedema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27016?source=see_link\">",
"     \"Popliteal (Baker's) cyst\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following clues point to venous insufficiency as the cause of lower extremity edema:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The edema is limited to the lower extremities and is often unilateral (particularly early) and is accompanied by venous abnormalities (telangiectasias, reticular veins, varicose veins), hyperpigmentation, or other signs of venous disease. By contrast, the edema in generalized edematous states is usually bilateral and is often not limited to the legs.",
"     </li>",
"     <li>",
"      The edema typically subsides with recumbency. While many other edematous states also improve in this setting, this finding distinguishes venous insufficiency from chronic lymphatic obstruction, which is often unilateral and may not subside with recumbency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=see_link\">",
"       \"Clinical manifestations and diagnosis of lymphedema\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The central venous pressure is normal, a finding that excludes heart failure as a cause for the edema. This distinction is more difficult when both heart failure and venous disease are present.",
"     </li>",
"     <li>",
"      Patients who have been given diuretics will have a poor response, and can develop signs of hypoperfusion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=see_link&amp;anchor=H14#H14\">",
"       \"Medical management of lower extremity chronic venous disease\", section on 'Diuretics'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Skin pigmentation changes/dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pigmentation changes are initially most prominent at the medial ankle, but subsequently may encroach upon the foot and lower leg (",
"    <a class=\"graphic graphic_picture graphicRef56758 \" href=\"UTD.htm?3/63/4080\">",
"     picture 4",
"    </a>",
"    ). Brown and blue-grey hyperpigmentation on the anterior lower leg is a common finding. The pigmentation is due to hemosiderin deposition which derives from the breakdown of red blood cells that have extravasated through damaged capillaries into the dermis.",
"   </p>",
"   <p>",
"    Individuals with functional venous disease due to venous reflux are prone to develop stasis dermatitis which is one of the most common and earliest dermatologic signs of chronic venous insufficiency. Stasis dermatitis is an inflammatory process that presents as an eczematous rash characterized by itching, erythema, scaling, weeping, erosions, and crusting (",
"    <a class=\"graphic graphic_picture graphicRef58465 \" href=\"UTD.htm?43/42/44719\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The pruritus associated with the dry, scaly skin can be difficult to relieve; excoriations are often present secondary to scratching, and can be a source of skin infection. Rashes mimicking the dermatitis on the legs can appear as eczematous patches on other body sites, or can present as a generalized body rash, an auto eczematous or \"id\" reaction (",
"    <a class=\"graphic graphic_picture graphicRef51553 \" href=\"UTD.htm?41/25/42399\">",
"     picture 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Atrophie blanche manifests as atrophic, hypopigmented patches with focal red punctate dots or telangiectasias, surrounded by hyperpigmentation. These are most often seen on the medial distal leg near the malleolus, or can occur within lipodermatosclerotic skin, where they correspond to points of avascular fibrosis (",
"    <a class=\"graphic graphic_picture graphicRef67105 \" href=\"UTD.htm?28/43/29360\">",
"     picture 7",
"    </a>",
"    ). These areas do not represent healed venous ulcers, but they are vulnerable to future ulceration because of poor perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13592/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6103?source=see_link\">",
"     \"Livedoid vasculopathy\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H15\">",
"     'Venous ulceration'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Lipodermatosclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic venous insufficiency of sufficient severity (eg, following severe cases of deep venous thrombosis or that associated with lymphatic compromise) may lead to the development of lipodermatosclerosis, a fibrosing panniculitis of the subcutaneous tissue. This disorder is characterized by a firm area of induration which is initially located at the medial ankle (",
"    <a class=\"graphic graphic_picture graphicRef65447 \" href=\"UTD.htm?11/14/11490\">",
"     picture 8",
"    </a>",
"    ). As the process progresses, the entire leg can become circumferentially involved with extension up to the mid leg in more advanced cases (",
"    <a class=\"graphic graphic_picture graphicRef76901 \" href=\"UTD.htm?25/57/26527\">",
"     picture 9",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The skin overlying the panniculitis is typically heavily pigmented and bound down to the subcutaneous tissues. The fibrosis may be so extensive and constrictive as to girdle and strangle the lower leg, further impeding lymphatic and venous flow. Brawny edema above the fibrotic area and on the foot below is seen in advanced cased of lipodermatosclerosis. The limb now resembles an inverted champagne bottle; the bulbous cork represents the lymphedematous foot, the fibrosed area the neck of the bottle, and edematous leg the body of the bottle (",
"    <a class=\"graphic graphic_picture graphicRef73283 \" href=\"UTD.htm?0/55/880\">",
"     picture 10",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients with lipodermatosclerosis are particularly prone to repeated bouts of cellulitis, usually caused by Staphylococcal or Streptococcal organisms (",
"    <a class=\"graphic graphic_picture graphicRef77986 \" href=\"UTD.htm?31/7/31871\">",
"     picture 11",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link\">",
"     \"Cellulitis and erysipelas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Venous ulceration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic venous disease is the most common cause of lower extremity ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13592/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. They are usually located low on the medial ankle over a perforating vein, or along the course of the great or small saphenous veins (",
"    <a class=\"graphic graphic_figure graphicRef55019 graphicRef52340 \" href=\"UTD.htm?5/25/5527\">",
"     figure 1A-B",
"    </a>",
"    ); they can occur more proximally on the leg if precipitated by trauma, but never in the forefoot or above the level of the knee. The ulcers may be multiple or single, and are exquisitely tender, shallow, exudative and have a granulation base (",
"    <a class=\"graphic graphic_picture graphicRef71020 \" href=\"UTD.htm?13/14/13536\">",
"     picture 12",
"    </a>",
"    ). The ulcer borders are usually irregular but not undermined. They can extend circumferentially around the leg if left untreated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13592/abstract/27-31\">",
"     27-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These characteristic findings often allow distinction between venous ulcers and the following types of ulcers that also appear on the lower extremities (",
"    <a class=\"graphic graphic_table graphicRef63577 \" href=\"UTD.htm?5/32/5645\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arterial ulcers are typically painful, and punched out or stellate in appearance. The surrounding skin is red and taut. Some arterial ulcers are pale; others may have a black or yellow eschar. On the leg, they are more often associated with trauma and commonly occur on the foot over pressure points. In addition, the leg",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      foot may display other signs of arterial insufficiency including thin atrophic and hairless skin, poor or absent pedal pulses, diminished capillary refill, or hypertrophic deformed nails. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=see_link\">",
"       \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neuropathic foot ulcers, including diabetic ulcers, most commonly occur at areas of increased pressure at sites of bony prominences, such as over the metatarsal heads. They typically are surrounded by a thick hyperkeratosis and the ulcer often has undermined borders (",
"      <a class=\"graphic graphic_picture graphicRef51991 \" href=\"UTD.htm?36/47/37631\">",
"       picture 13",
"      </a>",
"      ). The extremity and the ulcer are usually insensitive. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11464?source=see_link\">",
"       \"Evaluation of the diabetic foot\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other possible causes of ulcers include rheumatoid arthritis and other connective tissue diseases with associated vasculitis, hemoglobinopathies (eg, sickle cell disease), pyoderma gangrenosum, and tumors, especially squamous cell carcinoma and basal cell carcinoma. It may be necessary to have the ulcer biopsied in order to rule out these uncommon causes of lower extremity ulcers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/47/41714?source=see_link\">",
"       \"Patient information: Varicose veins and other vein disease in the legs (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/17/35091?source=see_link\">",
"       \"Patient information: Chronic venous disease (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic lower extremity venous disease is the most common vascular disorder encompassing the full spectrum of signs and symptoms as classified by the CEAP system (CEAP &Oslash; to 6). Advanced levels of chronic venous disease, collectively referred to as chronic venous insufficiency (ie, CEAP categories 4 to 6), are associated with chronic disability, diminished quality of life, and high health care costs. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common symptoms of lower extremity chronic venous disease are limb discomfort (ie, tired, heavy legs), pain, and limb swelling. Pain associated with venous disease is typically worse when standing or when seated with the feet dependent for prolonged periods of time, and improves with limb elevation and walking. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common clinical sign of lower extremity chronic venous disease is abnormal venous dilation (ie, telangiectasias, reticular veins, varicose veins). The signs of more advanced venous disease (ie, chronic venous insufficiency) include lower extremity edema, skin pigmentation,",
"      <span class=\"nowrap\">",
"       dermatitis/eczema,",
"      </span>",
"      lipodermatosclerosis, and ulceration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      About 20 percent of patients with symptoms consistent with venous disease have no visible clinical signs. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'No clinical signs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Telangiectasias are a confluence of dilated intradermal venules less than 1 millimeter in diameter and are the most frequently encountered manifestation of venous disease. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Telangiectasia/reticular veins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Varicose veins are subcutaneous dilated, tortuous veins greater than 3 millimeters in diameter. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Varicose veins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Edema is generally worse with prolonged standing and improves with leg elevation and walking. In the early stages of chronic venous insufficiency, edema may be present only at the end of the day; however, with time it can become persistent throughout the day. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Edema'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pigmentation associated with chronic venous insufficiency is derived from the breakdown of red blood cells that have extravasated through damaged capillaries into the dermis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Skin pigmentation changes/dermatitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stasis dermatitis is an inflammatory process that presents as an eczematous rash. The associated pruritus can be difficult to relieve. The resulting excoriations from scratching can be a source of skin infection, and areas of skin breakdown can develop into ulcers. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Skin pigmentation changes/dermatitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lipodermatosclerosis is a fibrosing panniculitis of the subcutaneous tissue. Patients with lipodermatosclerosis are particularly prone to repeated bouts of cellulitis. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Lipodermatosclerosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Venous ulcers are usually located low on the medial ankle or along the saphenous veins. Venous ulcers are tender, shallow, exudative and have a base of granulation tissue; these features usually distinguish venous ulcers from other types of ulcers that occur in the lower extremities. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Venous ulceration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/1\">",
"      Criqui MH, Jamosmos M, Fronek A, et al. Chronic venous disease in an ethnically diverse population: the San Diego Population Study. Am J Epidemiol 2003; 158:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/2\">",
"      Porter JM, Moneta GL. Reporting standards in venous disease: an update. International Consensus Committee on Chronic Venous Disease. J Vasc Surg 1995; 21:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/3\">",
"      Bergan JJ, Schmid-Sch&ouml;nbein GW, Smith PD, et al. Chronic venous disease. N Engl J Med 2006; 355:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/4\">",
"      O'Donnell TF Jr, Browse NL, Burnand KG, Thomas ML. The socioeconomic effects of an iliofemoral venous thrombosis. J Surg Res 1977; 22:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/5\">",
"      Cornwall JV, Dor&eacute; CJ, Lewis JD. Leg ulcers: epidemiology and aetiology. Br J Surg 1986; 73:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/6\">",
"      Dalen JE, Paraskos JA, Ockene IS, et al. Venous thromboembolism. Scope of the problem. Chest 1986; 89:370S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/7\">",
"      Chiesa R, Marone EM, Limoni C, et al. Chronic venous disorders: correlation between visible signs, symptoms, and presence of functional disease. J Vasc Surg 2007; 46:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/8\">",
"      Hanrahan LM, Araki CT, Rodriguez AA, et al. Distribution of valvular incompetence in patients with venous stasis ulceration. J Vasc Surg 1991; 13:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/9\">",
"      Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 2009; 78:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/10\">",
"      Scott TE, Mendez MV, LaMorte WW, et al. Are varicose veins a marker for susceptibility to coronary heart disease in men? Results from the Normative Aging Study. Ann Vasc Surg 2004; 18:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/11\">",
"      M&auml;kivaara LA, Ahti TM, Luukkaala T, et al. Persons with varicose veins have a high subsequent incidence of arterial disease: a population-based study in Tampere, Finland. Angiology 2007; 58:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/12\">",
"      Kurz X, Lamping DL, Kahn SR, et al. Do varicose veins affect quality of life? Results of an international population-based study. J Vasc Surg 2001; 34:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/13\">",
"      Baker DM, Turnbull NB, Pearson JC, Makin GS. How successful is varicose vein surgery? A patient outcome study following varicose vein surgery using the SF-36 Health Assessment Questionnaire. Eur J Vasc Endovasc Surg 1995; 9:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/14\">",
"      Garratt AM, Macdonald LM, Ruta DA, et al. Towards measurement of outcome for patients with varicose veins. Qual Health Care 1993; 2:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/15\">",
"      Smith JJ, Garratt AM, Guest M, et al. Evaluating and improving health-related quality of life in patients with varicose veins. J Vasc Surg 1999; 30:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/16\">",
"      Palfreyman S. Assessing the impact of venous ulceration on quality of life. Nurs Times 2008; 104:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/17\">",
"      Hareendran A, Bradbury A, Budd J, et al. Measuring the impact of venous leg ulcers on quality of life. J Wound Care 2005; 14:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/18\">",
"      Almeida JI, Kaufman J, G&ouml;ckeritz O, et al. Radiofrequency endovenous ClosureFAST versus laser ablation for the treatment of great saphenous reflux: a multicenter, single-blinded, randomized study (RECOVERY study). J Vasc Interv Radiol 2009; 20:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/19\">",
"      Kahn SR, Hirsch A, Shrier I. Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis. Arch Intern Med 2002; 162:1144.",
"     </a>",
"    </li>",
"    <li>",
"     Renner, R. J Dtsch Dermatol Ges 2009 [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/21\">",
"      Newland MR, Patel AR, Prieto L, et al. Neuropathy and gait disturbances in patients with venous disease: a pilot study. Arch Dermatol 2009; 145:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/22\">",
"      Padberg FT Jr, Maniker AH, Carmel G, et al. Sensory impairment: a feature of chronic venous insufficiency. J Vasc Surg 1999; 30:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/23\">",
"      Shiman MI, Pieper B, Templin TN, et al. Venous ulcers: A reappraisal analyzing the effects of neuropathy, muscle involvement, and range of motion upon gait and calf muscle function. Wound Repair Regen 2009; 17:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/24\">",
"      Browse NL, Burnand KG. The cause of venous ulceration. Lancet 1982; 2:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/25\">",
"      Baker SR, Stacey MC, Jopp-McKay AG, et al. Epidemiology of chronic venous ulcers. Br J Surg 1991; 78:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/26\">",
"      Callam MJ, Harper DR, Dale JJ, Ruckley CV. Chronic ulcer of the leg: clinical history. Br Med J (Clin Res Ed) 1987; 294:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/27\">",
"      Panny M, Ammer K, Kundi M, et al. Severity of chronic venous disorders and its relationship to the calf muscle pump. Vasa 2009; 38:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/28\">",
"      Araki CT, Back TL, Padberg FT, et al. The significance of calf muscle pump function in venous ulceration. J Vasc Surg 1994; 20:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/29\">",
"      Recek C. Conception of the venous hemodynamics in the lower extremity. Angiology 2006; 57:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/30\">",
"      Padberg FT Jr, Johnston MV, Sisto SA. Structured exercise improves calf muscle pump function in chronic venous insufficiency: a randomized trial. J Vasc Surg 2004; 39:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13592/abstract/31\">",
"      Simka M. Calf muscle pump impairment and delayed healing of venous leg ulcers: air plethysmographic findings. J Dermatol 2007; 34:537.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8198 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.81.197.98-2E1E3D353B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_17_13592=[""].join("\n");
var outline_f13_17_13592=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      APPROACH TO THE PATIENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors for venous disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Medical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Quality of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PHYSICAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL SIGNS BY CEAP CATEGORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      No clinical signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Telangiectasia/reticular veins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Varicose veins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Skin pigmentation changes/dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Lipodermatosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Venous ulceration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8198\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8198|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/46/36579\" title=\"figure 1A\">",
"      Superficial veins of leg anterior view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/42/42671\" title=\"figure 1B\">",
"      Superficial veins of lower leg posterior view",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8198|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/58/18351\" title=\"picture 1\">",
"      Telangiectasia of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/36/40526\" title=\"picture 2\">",
"      Severe varicose veins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/60/34766\" title=\"picture 3\">",
"      Telangiectasia reticular veins and mild ankle edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/63/4080\" title=\"picture 4\">",
"      Skin changes of chronic venous insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/42/44719\" title=\"picture 5\">",
"      Advanced stasis dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/25/42399\" title=\"picture 6\">",
"      Autoeczematous reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/43/29360\" title=\"picture 7\">",
"      Atrophie blanche lipodermatosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/14/11490\" title=\"picture 8\">",
"      Stasis dermatitis sclerotic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/57/26527\" title=\"picture 9\">",
"      Lipodermatosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/55/880\" title=\"picture 10\">",
"      Advanced lipodermatosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/7/31871\" title=\"picture 11\">",
"      Cellulitis with venous insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/14/13536\" title=\"picture 12\">",
"      Venous stasis ulcer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/47/37631\" title=\"picture 13\">",
"      Wagner grade 2 ulcer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8198|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/45/10973\" title=\"table 1\">",
"      CEAP classification for chronic venous disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/3/5181\" title=\"table 2\">",
"      Major causes of edema by primary mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/32/5645\" title=\"table 3\">",
"      Differentiation of foot ulcers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?34/0/34818?source=related_link\" title=\"calculator 1\">",
"      Calculator: Venous clinical severity score",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31879?source=related_link\">",
"      Approach to the patient with sensory loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11735?source=related_link\">",
"      Classification of lower extremity chronic venous disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=related_link\">",
"      Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=related_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14486?source=related_link\">",
"      Clinical manifestations and evaluation of chronic critical limb ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11464?source=related_link\">",
"      Evaluation of the diabetic foot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6103?source=related_link\">",
"      Livedoid vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20810?source=related_link\">",
"      Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=related_link\">",
"      Medical management of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=related_link\">",
"      Overview and management of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/34/36393?source=related_link\">",
"      Pathophysiology and etiology of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/17/35091?source=related_link\">",
"      Patient information: Chronic venous disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/47/41714?source=related_link\">",
"      Patient information: Varicose veins and other vein disease in the legs (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27016?source=related_link\">",
"      Popliteal (Baker's) cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23127?source=related_link\">",
"      Post-thrombotic (postphlebitic) syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_17_13593="Pathogenesis of paroxysmal nocturnal hemoglobinuria: Missing cell proteins";
var content_f13_17_13593=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of paroxysmal nocturnal hemoglobinuria: Missing cell proteins",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/17/13593/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/17/13593/contributors\">",
"     Wendell F Rosse, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/17/13593/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/17/13593/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/17/13593/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/17/13593/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/17/13593/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paroxysmal nocturnal hemoglobinuria (PNH) was one of the first hematologic disorders given a clear clinical description, because the defining symptom, dark urine at night, was distinctive and easily observed. It was subsequently realized that the pigment was hemoglobin, which resulted from the breakdown or hemolysis of red cells. The hemolysis was subsequently found to be due to the action of complement on abnormal red cells; these red cells were then shown to be deficient in several proteins which were tethered to the cell membrane by a glycosylphosphatidylinositol (GPI) anchor. This finding uncovered the fundamental pathogenic defect in PNH: an inability to produce the GPI anchor due to a defect in the PIG-A gene [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42392?source=see_link\">",
"     \"Pathogenesis of paroxysmal nocturnal hemoglobinuria: Absence of the GPI anchor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will discuss the cell proteins that are missing in PNH [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/2\">",
"     2",
"    </a>",
"    ]. How these abnormalities may lead to the clinical manifestations of the disease (eg, hemolysis, venous thrombosis, bone marrow aplasia), as well as the diagnosis and treatment of this condition, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14121?source=see_link\">",
"     \"Clinical manifestations of paroxysmal nocturnal hemoglobinuria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17082?source=see_link\">",
"     \"Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MISSING PROTEINS IN PNH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the discovery of the GPI anchor, a number of proteins have been found that are tethered to the membrane by a GPI tail. Such proteins are often defined by their release from the cell membrane by the bacterial enzyme phosphatidylinositol-specific phospholipase C (PIPLC) or, less commonly, by the demonstration of the GPI anchor on the purified protein. Approximately 20 of these proteins have been demonstrated on human hematopoietic cells, and are therefore deficient on the abnormal cells in PNH [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Alkaline phosphatase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first biochemical abnormality described in PNH was the lack of the enzyme leukocyte alkaline phosphatase. This finding was uncovered during a survey of hematologic diseases, which also found that the enzyme was diminished in the cells of chronic granulocytic leukemia (CML) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/3\">",
"     3",
"    </a>",
"    ]. In PNH, a proportion of the neutrophils appeared to have no enzyme, while the rest seemed to have normal amounts [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/4\">",
"     4",
"    </a>",
"    ]; by comparison, all cells in CML had a variable degree of deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/3\">",
"     3",
"    </a>",
"    ]. The mechanism of the loss of alkaline phosphatase differs in the two disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Acetylcholinesterase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second enzyme found to be diminished in PNH was erythrocyte acetylcholinesterase [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/5\">",
"     5",
"    </a>",
"    ]. When the red cells were later separated into complement sensitive and insensitive populations, the degree of deficiency in each population was directly related to the degree of complement sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/6\">",
"     6",
"    </a>",
"    ]; however, no causal relationship between the deficiency of the enzyme and the sensitivity to complement could be demonstrated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Decay accelerating factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first protein found to be lacking on PNH red cells that appeared to have a functional role in the pathogenesis of the disease was identified during the process of analyzing the control of complement activation on the cell surface. Previous studies had identified a cellular component (decay accelerating factor [DAF], CD55) that downregulated the activity of the C4b2a complex (a combination of C4b and C2a that activates C3 by enzymatic cleavage) by accelerating the decay of this bimolecular enzyme complex [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/7\">",
"     7",
"    </a>",
"    ]. The homologous component was subsequently identified on human red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=see_link\">",
"     \"Complement pathways\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10854?source=see_link\">",
"     \"Regulators and receptors of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    DAF was then found to be missing on the red cells of patients with PNH [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. This deficiency was assumed to account for the greatly increased deposition of activated C3b on PNH cells when complement was activated either by the classical (antibody-driven) or alternative (antibody-independent) pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, several observations indicated that the absence of DAF was not the entire reason for the unusual sensitivity of PNH red cells to complement:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Much more lysis of PNH cells was observed when the lysis of normal and PNH red cells bearing the same amount of bound C3 were compared [",
"      <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inhibition of the functional activity of DAF by antibody only slightly increased the lysis of the red cells by complement [",
"      <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients congenitally lacking DAF had only marginally increased sensitivity to complement [",
"      <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result, a second defect in PNH cells was postulated to contribute to the increased sensitivity to complement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Importance of CD59",
"    </span>",
"    &nbsp;&mdash;&nbsp;The studies mentioned above led to the identification of a second protein, CD59 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/17\">",
"     17",
"    </a>",
"    ], which has also been called membrane inhibitor of reactive lysis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/18\">",
"     18",
"    </a>",
"    ], protectin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/19\">",
"     19",
"    </a>",
"    ], homologous restriction factor [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/20\">",
"     20",
"    </a>",
"    ], and membrane attack complex inhibitory factor (MACIF) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/21\">",
"     21",
"    </a>",
"    ]. CD59 inhibits the formation of polymeric C9 (the complex arising from complement activation that results in membrane disruption) by restricting the interaction of hydrophilic fluid-phase C9 with either C8 of the C5b-8 complex or C9 itself [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/22-24\">",
"     22-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CD59 is partially or completely missing from the hematopoietic cells in PNH [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/18,25-30\">",
"     18,25-30",
"    </a>",
"    ]. It is this deficiency that explains much of the increased clinical hemolysis and thrombosis in this disorder. This conclusion is suggested by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Functional inhibition of CD59 results in cells exquisitely sensitive to the hemolytic action of complement [",
"      <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The replacement of CD59 on abnormal PNH cells virtually restores the resistance to complement [",
"      <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The red cells of a patient who lacks CD59 because of a homozygous genetic defect are as sensitive as abnormal PNH cells to complement lysis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/32\">",
"       32",
"      </a>",
"      ]. This is in contrast to the slight increase in complement sensitivity in patients congenitally deficient in DAF [",
"      <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CD59-deficient mice display spontaneous intravascular hemolysis, which was increased following activation of complement [",
"      <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other GPI-linked proteins have been found to be absent on PNH cells. The effect of their absence remains unclear. These include C8 binding protein, lymphocyte function associated-III, Fc receptor IIIa, endotoxin binding protein receptor, Campath-1 (CDw52), CD24, CD48, and CD66 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/20,34-43\">",
"     20,34-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two of the missing GPI-linked proteins may contribute to the increased incidence of thrombosis in PNH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14121?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations of paroxysmal nocturnal hemoglobinuria\", section on 'Venous thrombosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urokinase plasminogen activator receptor, the lack of which may decrease local fibrinolysis.",
"     </li>",
"     <li>",
"      Tissue factor pathway inhibitor, the lack of which may increase the procoagulant activity of tissue factor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although many proteins have been found to be missing on the blood cells of patients with PNH, most of the clinical manifestations of the disease are due to the lack of the complement regulating protein, CD59. The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    , a monoclonal antibody that binds to the C5 component of complement and inhibits terminal complement activation, appears to ameliorate not only the hemolysis of red cells, but also the thrombophilia that is a significant part of the clinical picture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17082?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria\", section on 'Eculizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no evidence that this drug affects the deficiency of hematopoiesis that is part of the syndrome, suggesting that this aspect is not due to the effects of a defect in complement regulation. It is somewhat surprising that so many proteins involved in immune function are missing in the abnormal cell of PNH and yet no identifiable immune deficiency has been attributed to patients with this disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Missing blood group antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absence of certain blood group antigens on PNH cells is due to a number of missing cell surface proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/1,44,45\">",
"     1,44,45",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The absence of Cromer blood group antigens is due to a deficiency of decay accelerating factor [",
"      <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/44,46\">",
"       44,46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The missing Cartwright",
"      <span class=\"nowrap\">",
"       (Yta/Ytb)",
"      </span>",
"      antigens have been attributed to the absence of acetylcholinesterase [",
"      <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/47,48\">",
"       47,48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The protein bearing the JMH antigen has been shown to be a glycoprotein of 76 kD whose function is unknown [",
"      <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of other antigens, such as Dombrock, Holley-Gregory",
"    <span class=\"nowrap\">",
"     [Hy/Gya],",
"    </span>",
"    and JMH , are also missing in patients with PNH [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/45,49\">",
"     45,49",
"    </a>",
"    ]. The identity of these molecules is not certain, but they are thought to be different for each blood group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DEFICIENCY OF GPI-LINKED PROTEINS IN BLOOD CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since nearly all the proteins missing in PNH can be detected with monoclonal antibodies, the expression of these proteins can be examined on various hematopoietic cells. The absence of a GPI-linked protein on a particular cell is assumed to result from a defect in the original precursor hematopoietic stem cell.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hematopoietic progenitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic progenitors can be identified by the presence or absence of marker proteins associated with maturation. Stem cells, defined as cells that can differentiate into any of the hematopoietic cell lineages, can be found among the cells that bear the CD34 antigen but not the CD38 antigen",
"    <span class=\"nowrap\">",
"     (CD34+/CD38-)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/50\">",
"     50",
"    </a>",
"    ]. In normal marrow, stem cells bear the CD55 and CD59 antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/51\">",
"     51",
"    </a>",
"    ]. In PNH marrow,",
"    <span class=\"nowrap\">",
"     CD34+/CD38-",
"    </span>",
"    cells can be found with and without CD55 and CD59 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/52\">",
"     52",
"    </a>",
"    ]; the proportion of CD59- precursors parallels the proportion of such defective cells in the granulocyte population (see below).",
"   </p>",
"   <p>",
"    Hematopoietic precursors can also be found in the peripheral blood, especially after being mobilized by cytokines or chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Again, both CD59+ and CD59- cells can be found among the",
"    <span class=\"nowrap\">",
"     CD34+/CD38-",
"    </span>",
"    population; however, the proportion of CD59+ cells appears to be greater than in the marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasionally, GPI-deficient cells, usually granulocytes, are detected in the marrow several months before they are found in the peripheral blood [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/7\">",
"     7",
"    </a>",
"    ]. This setting has been classified as the \"preclinical\" state of PNH [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Peripheral blood cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;In all patients with PNH, cells partially or completely lacking the GPI-linked proteins may be found among red cells, granulocytes, monocytes, lymphocytes, and platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/27,38,57-61\">",
"     27,38,57-61",
"    </a>",
"    ]. The proportion of abnormal cells varies greatly from patient to patient; in addition, the proportion may vary greatly from one cell type to another within the same patient, as well as with duration of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not clear what effect, if any, the lack of GPI-linked proteins in lymphocytes, granulocytes and monocytes has on the overall function of the immune system. Patients with PNH are not clearly immunodeficient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     PNH cells in other conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;By the use of very sensitive flow cytometric techniques, very small numbers of granulocytes (approximately 22 per one million cells) lacking the GPI-anchored proteins can be found in the blood of normal individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/63\">",
"     63",
"    </a>",
"    ]. Many patients with aplastic anemia or myelodysplastic syndrome also have small populations of such cells [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/64\">",
"     64",
"    </a>",
"    ]; these patients have no evidence of hemolysis or other manifestations of PNH unrelated to deficient hematopoiesis. These small populations may increase to result in clinical PNH (17 percent in one series), remain the same size over time (59 percent), or disappear (24 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/586?source=see_link&amp;anchor=H13#H13\">",
"     \"Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis\", section on 'Clonal and genetic disorders'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29930?source=see_link&amp;anchor=H28#H28\">",
"     \"Aplastic anemia: Prognosis and treatment\", section on 'Occurrence of clonal disorders'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=see_link&amp;anchor=H2816177#H2816177\">",
"     \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'PNH-positive cells'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Erythrocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different populations of red cells have been defined in PNH according to the status of GPI-linked proteins:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      PNH type I cells &mdash; normal",
"     </li>",
"     <li>",
"      PNH type II cells &mdash; partial absence",
"     </li>",
"     <li>",
"      PNH type III cells &mdash; complete absence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In almost all patients with PNH, the PNH type III cells completely lacking in GPI-linked proteins may be found as a discrete population. These cells are the most sensitive to complement and the most readily lysed in vivo. The proportion may range from 1 to 5 percent (the minimal number causing clinical effects) to as high as 98 percent; most patients have fewer than 80 percent of these cells.",
"   </p>",
"   <p>",
"    Cells of partial deficiency (PNH type II cells) occur in about one-half of the patients examined. In some patients, they appear to represent a distinct population of cells; in others, they seem to be \"transitional\" between the cells bearing normal amounts of protein and those bearing none. In one study, PNH type II cells accounted for more than 20 percent of erythrocytes in only 13 percent of patients.",
"   </p>",
"   <p>",
"    PNH type II cells were first identified in studies quantitating the sensitivity of red cells to the lytic action of complement [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. They are more easily demonstrated using flow cytometry. Studies using murine antibodies and two-color flow cytometry have shown that the life span of PNH type III red cells varied from 17 to 60 days (normal 110 to 120 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/68\">",
"     68",
"    </a>",
"    ]. The life span of PNH type II red cells varied with the residual expression of CD59; cells with 15 to 20 percent of the normal amount of CD59 were protected against in vivo hemolysis although they were sensitive to complement-mediated lysis in vitro.",
"   </p>",
"   <p>",
"    Most patients maintain a detectable residual normal clone of cells bearing normal amounts of GPI-linked proteins (PNH type I cells) although the number may be very small; in one series, for example, only 4 of 109 patients had no detectable PNH type I cells.",
"   </p>",
"   <p>",
"    The reason for the existence of PNH type II cells is unclear. A number of explanations have been advanced:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In some cases, a defect in the gene for the PIG-A protein causes limited production of the gene product or a gene product of diminished activity (missense mutations). This mechanism implies that some patients with both PNH type II and PNH type III cells have more than one clone of abnormal cells. As mentioned above, mutational analysis has revealed the existence of multiple clonal abnormalities in some individuals.",
"     </li>",
"     <li>",
"      Cells of intermediate abnormality may be generated in the circulation by the transfer of small amounts of GPI-anchored proteins from the surface of cells on which they exist to those on which they are absent [",
"      <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/69\">",
"       69",
"      </a>",
"      ]. Some patients have reticulocytes of intermediate abnormality, while others with circulating PNH type II cells have no reticulocytes of intermediate abnormality [",
"      <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/70\">",
"       70",
"      </a>",
"      ]. If transfer in the circulation does occur, this finding would suggest that cells that had been in the circulation for only a short time (such as reticulocytes) had not had time to acquire or exchange GPI-anchored proteins.",
"     </li>",
"     <li>",
"      Small amounts of the gene product necessary for the production of the GPI anchor may arise from other sources in the genome, particularly a pseudogene on chromosome 12 [",
"      <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/71,72\">",
"       71,72",
"      </a>",
"      ]. However, no data currently exist to support this possibility. In addition, the sequence of the pseudogene is so corrupted that it is unlikely that any gene product results from this locus.",
"     </li>",
"     <li>",
"      The PIG-A gene, which is located near the end of the X chromosome, may not be entirely inactivated by \"lyonization\" of one of the X chromosomes. This mechanism would only apply to females, but is also unsupported by data.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Granulocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulocytes can also be analyzed for the deficiency of GPI-linked proteins by flow cytometry. The circulating life span of the abnormal PNH granulocyte is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/73\">",
"     73",
"    </a>",
"    ]; whereas that of the abnormal PNH red cell is shortened [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/74\">",
"     74",
"    </a>",
"    ]. Thus, the proportion of abnormal circulating granulocytes more closely reflects the proportion delivered to the circulation each day and is therefore more likely to correlate with the stem cell findings.",
"   </p>",
"   <p>",
"    The defect in granulocytes can be illustrated by the findings in a study of 67 patients with PNH:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      94 percent had a population of granulocytes in which GPI-linked proteins were completely lacking (PNH type III cells). In almost one-half of patients, more than 80 percent of the granulocytes were PNH type III type cells. Approximately 15 percent of patients had no normal granulocytes. This supports other observations that the proportion of PNH type III granulocytes is nearly always greater than the proportion of PNH type III red cells.",
"     </li>",
"     <li>",
"      Fewer patients demonstrated partially deficient (PNH type II) granulocytes, and small \"transition\" type populations were unusual. This may be because granulocytes have a short life span and therefore deficient cells do not have time to acquire GPI anchored proteins from replete cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Lymphocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphocytes lacking the GPI-linked proteins are present in all patients with PNH [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/36,42,75,76\">",
"     36,42,75,76",
"    </a>",
"    ], but occasionally only in very small numbers. In most patients, the percentage of GPI-deficient natural killer (NK) cells is considerably higher than B or T cells, although there may be low absolute number of NK cells [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/77\">",
"     77",
"    </a>",
"    ]. The number of abnormal B cells is generally greater than the number of abnormal T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/76\">",
"     76",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    In patients undergoing spontaneous remission of PNH, T cells lacking GPI-linked proteins can be found long after the disappearance of other abnormal cell lines [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/78,79\">",
"     78,79",
"    </a>",
"    ], suggesting that long-lived T cells persist long after the GPI-deficient stem cell pool has disappeared. As a result, the proportion of abnormal T cells (which is almost always less than the proportion of abnormal granulocytes) roughly correlates with the duration of disease.",
"   </p>",
"   <p>",
"    The following functional abnormalities have been identified in the deficient lymphocytes of patients with PNH:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The abnormal cells do not respond to some lectin stimuli as well as normal cells [",
"      <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/80,81\">",
"       80,81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Compared with normal T cells, GPI-deficient T cells are stimulated less by normal B cells in mixed cultures; in contrast, normal T cells are stimulated normally by GPI-deficient B cells [",
"      <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the majority of the peripheral blood lymphocytes have the \"naive\" CD45 phenotype (CD45 RA+) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/76,80\">",
"     76,80",
"    </a>",
"    ], they can be converted to the \"memory\" phenotype in vitro as well as normal cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Monocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal monocytes in PNH are usually demonstrated by deficiency of the receptor for the lipopolysaccharide-binding protein CD14 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/83\">",
"     83",
"    </a>",
"    ]; however, antibodies to other proteins, such as urokinase receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/39\">",
"     39",
"    </a>",
"    ], CD55, and CD59 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/84\">",
"     84",
"    </a>",
"    ], can also be used. In general, the proportion of abnormal monocytes closely parallels the proportion of abnormal granulocytes. The abnormal monocytes are less easily stimulated by lipopolysaccharide than normal cells [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/85\">",
"     85",
"    </a>",
"    ]. Although macrophages have not been examined for the deficiency of GPI-linked proteins, they are also presumably deficient since they are descended from monocytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Platelets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with normal platelets, platelets in PNH are more susceptible to the lytic action of complement [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/86\">",
"     86",
"    </a>",
"    ]. Although the absence of CD55 and CD59 on platelets is easily documented by flow cytometry, the ability to distinguish normal from abnormal is not as great as with other hematopoietic cells. However, the lack of GPI-linked proteins has a substantial effect on the function of the platelets.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5857834\">",
"    <span class=\"h2\">",
"     GPI-linked proteins and apoptosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have suggested that GPI deficient cells are more resistant to apoptosis (programmed cell death) than GPI-replete cells [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/87\">",
"     87",
"    </a>",
"    ]. The reason for this is not clear but may have to do with the fact that GPI-anchored proteins associate with the cholesterol-sphingomyelin rich lipid rafts [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/88\">",
"     88",
"    </a>",
"    ]. Studies of GPI-deficient PNH-like cells have shown defective transduction of the cell death signal [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/89\">",
"     89",
"    </a>",
"    ], which may be due to the lack of CD24, at least in B lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13593/abstract/90\">",
"     90",
"    </a>",
"    ]. Resistance to apoptosis has been suggested as a cause of enrichment of the bone marrow with these deficient cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13962299\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fundamental pathogenic defect in paroxysmal nocturnal hemoglobinuria (PNH) is an inability to produce the glycosylphosphatidylinositol (GPI) anchor due to a defect in the PIG-A gene. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42392?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis of paroxysmal nocturnal hemoglobinuria: Absence of the GPI anchor\", section on 'Glycosylphosphatidylinositol anchor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 20 proteins have been found that are tethered to the membrane by a GPI tail on human hematopoietic cells, and are therefore deficient on the abnormal cells in PNH. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Missing proteins in PNH'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CD59, also called membrane inhibitor of reactive lysis, is partially or completely missing from the hematopoietic cells in PNH, explaining much of the increased clinical hemolysis and thrombosis in this disorder. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Importance of CD59'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In all patients with PNH, cells partially or completely lacking GPI-linked proteins may be found among red cells, granulocytes, monocytes, lymphocytes, and platelets. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Deficiency of GPI-linked proteins in blood cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The demonstration of the lack of the GPI anchor",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      one or more of the missing proteins constitute the definitive diagnostic test for PNH. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17082?source=see_link&amp;anchor=H4#H4\">",
"       \"Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria\", section on 'Expression of GPI anchored proteins'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/1\">",
"      Rosse WF. Paroxysmal nocturnal hemoglobinuria as a molecular disease. Medicine (Baltimore) 1997; 76:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/2\">",
"      Hillmen P, Richards SJ. Implications of recent insights into the pathophysiology of paroxysmal nocturnal haemoglobinuria. Br J Haematol 2000; 108:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/3\">",
"      BECK WS, VALENTINE WN. Biochemical studies on leucocytes. II. Phosphatase activity in chronic lymphatic leucemia, acute leucemia, and miscellaneous hematologic conditions. J Lab Clin Med 1951; 38:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/4\">",
"      Lewis SM, Dacie JV. Neutrophil (leucocyte) alkaline phosphatase in paroxysmal nocturnal haemoglobinuria. Br J Haematol 1965; 11:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/5\">",
"      AUDITORE JV, HARTMANN RC, FLEXNER JM, BALCHUM OJ. The erythrocyte acetylcholinesterase enzyme in paroxysmal nocturnal hemoglobinuria. Arch Pathol 1960; 69:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/6\">",
"      Rosse WF, Gutterman LA. The effect of iron therapy in paroxysmal nocturnal hemoglobinuria. Blood 1970; 36:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/7\">",
"      Nakakuma H, Nagakura S, Iwamoto N, et al. Paroxysmal nocturnal hemoglobinuria clone in bone marrow of patients with pancytopenia. Blood 1995; 85:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/8\">",
"      Nicholson-Weller A, Burge J, Fearon DT, et al. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol 1982; 129:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/9\">",
"      Nicholson-Weller A, Spicer DB, Austen KF. Deficiency of the complement regulatory protein, \"decay-accelerating factor,\" on membranes of granulocytes, monocytes, and platelets in paroxysmal nocturnal hemoglobinuria. N Engl J Med 1985; 312:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/10\">",
"      Pangburn MK, Schreiber RD, M&uuml;ller-Eberhard HJ. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A 1983; 80:5430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/11\">",
"      Logue GL, Rosse WF, Adams JP. Mechanisms of immune lysis of red blood cells in vitro. I. Paroxysmal nocturnal hemoglobinuria cells. J Clin Invest 1973; 52:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/12\">",
"      Parker CJ, Baker PJ, Rosse WF. Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest 1982; 69:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/13\">",
"      Rosse WF, Logue GL, Adams J, Crookston JH. Mechanisms of immune lysis of the red cells in hereditary erythroblastic multinuclearity with a positive acidified serum test and paroxysmal nocturnal hemoglobinuria. J Clin Invest 1974; 53:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/14\">",
"      Medof ME, Gottlieb A, Kinoshita T, et al. Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes. J Clin Invest 1987; 80:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/15\">",
"      Merry AH, Rawlinson VI, Uchikawa M, et al. Studies on the sensitivity to complement-mediated lysis of erythrocytes (Inab phenotype) with a deficiency of DAF (decay accelerating factor). Br J Haematol 1989; 73:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/16\">",
"      Telen MJ, Green AM. The Inab phenotype: characterization of the membrane protein and complement regulatory defect. Blood 1989; 74:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/17\">",
"      Davies A, Simmons DL, Hale G, et al. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med 1989; 170:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/18\">",
"      Holguin MH, Fredrick LR, Bernshaw NJ, et al. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest 1989; 84:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/19\">",
"      Rooney IA, Davies A, Griffiths D, et al. The complement-inhibiting protein, protectin (CD59 antigen), is present and functionally active on glomerular epithelial cells. Clin Exp Immunol 1991; 83:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/20\">",
"      Zalman LS, Wood LM, M&uuml;ller-Eberhard HJ. Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci U S A 1986; 83:6975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/21\">",
"      Sugita Y, Nakano Y, Oda E, et al. Determination of carboxyl-terminal residue and disulfide bonds of MACIF (CD59), a glycosyl-phosphatidylinositol-anchored membrane protein. J Biochem 1993; 114:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/22\">",
"      Meri S, Morgan BP, Davies A, et al. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 1990; 71:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/23\">",
"      Rollins SA, Sims PJ. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol 1990; 144:3478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/24\">",
"      Rollins SA, Zhao J, Ninomiya H, Sims PJ. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. J Immunol 1991; 146:2345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/25\">",
"      Okada N, Harada R, Okada H. Erythrocytes of patients with paroxysmal nocturnal haemoglobinuria acquire resistance to complement attack by purified 20-kD homologous restriction factor. Clin Exp Immunol 1990; 80:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/26\">",
"      Fletcher A, Bryant JA, Gardner B, et al. New monoclonal antibodies in CD59: use for the analysis of peripheral blood cells from paroxysmal nocturnal haemoglobinuria (PNH) patients and for the quantitation of CD59 on normal and decay accelerating factor (DAF)-deficient erythrocytes. Immunology 1992; 75:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/27\">",
"      Hall SE, Rosse WF. The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. Blood 1996; 87:5332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/28\">",
"      Nilsson B, Hagstr&ouml;m U, Englund A, S&auml;fwenberg J. A simplified assay for the specific diagnosis of paroxysmal nocturnal hemoglobinuria: detection of DAF(CD55)- and HRF20(CD59)- erythrocytes in microtyping cards. Vox Sang 1993; 64:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/29\">",
"      Schubert J, Alvarado M, Uciechowski P, et al. Diagnosis of paroxysmal nocturnal haemoglobinuria using immunophenotyping of peripheral blood cells. Br J Haematol 1991; 79:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/30\">",
"      Shichishima T, Terasawa T, Hashimoto C, et al. Heterogenous expression of decay accelerating factor and CD59/membrane attack complex inhibition factor on paroxysmal nocturnal haemoglobinuria (PNH) erythrocytes. Br J Haematol 1991; 78:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/31\">",
"      Holguin MH, Wilcox LA, Bernshaw NJ, et al. Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria. J Clin Invest 1989; 84:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/32\">",
"      Yamashina M, Ueda E, Kinoshita T, et al. Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1990; 323:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/33\">",
"      Holt DS, Botto M, Bygrave AE, et al. Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria. Blood 2001; 98:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/34\">",
"      Sch&ouml;nermark S, Rauterberg EW, Shin ML, et al. Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor. J Immunol 1986; 136:1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/35\">",
"      H&auml;nsch GM, Sch&ouml;nermark S, Roelcke D. Paroxysmal nocturnal hemoglobinuria type III. Lack of an erythrocyte membrane protein restricting the lysis by C5b-9. J Clin Invest 1987; 80:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/36\">",
"      Selvaraj P, Dustin ML, Silber R, et al. Deficiency of lymphocyte function-associated antigen 3 (LFA-3) in paroxysmal nocturnal hemoglobinuria. Functional correlates and evidence for a phosphatidylinositol membrane anchor. J Exp Med 1987; 166:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/37\">",
"      Selvaraj P, Rosse WF, Silber R, Springer TA. The major Fc receptor in blood has a phosphatidylinositol anchor and is deficient in paroxysmal nocturnal haemoglobinuria. Nature 1988; 333:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/38\">",
"      van der Schoot CE, Huizinga TW, van 't Veer-Korthof ET, et al. Deficiency of glycosyl-phosphatidylinositol-linked membrane glycoproteins of leukocytes in paroxysmal nocturnal hemoglobinuria, description of a new diagnostic cytofluorometric assay. Blood 1990; 76:1853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/39\">",
"      Ploug M, Plesner T, R&oslash;nne E, et al. The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. Blood 1992; 79:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/40\">",
"      Haziot A, Chen S, Ferrero E, et al. The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. J Immunol 1988; 141:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/41\">",
"      Simmons DL, Tan S, Tenen DG, et al. Monocyte antigen CD14 is a phospholipid anchored membrane protein. Blood 1989; 73:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/42\">",
"      Nagakura S, Kawaguchi T, Horikawa K, et al. A deficiency in CDw52 (CAMPATH-1 antigen) of paroxysmal nocturnal hemoglobinuria lymphocytes. Blood 1993; 82:3790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/43\">",
"      Mayne KM, Pulford K, Jones M, et al. Antibody By114 is selective for the 90 kD PI-linked component of the CD66 antigen: a new reagent for the study of paroxysmal nocturnal haemoglobinuria. Br J Haematol 1993; 83:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/44\">",
"      Telen MJ, Hall SE, Green AM, et al. Identification of human erythrocyte blood group antigens on decay-accelerating factor (DAF) and an erythrocyte phenotype negative for DAF. J Exp Med 1988; 167:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/45\">",
"      Telen MJ, Rosse WF, Parker CJ, et al. Evidence that several high-frequency human blood group antigens reside on phosphatidylinositol-linked erythrocyte membrane proteins. Blood 1990; 75:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/46\">",
"      Spring FA, Judson PA, Daniels GL, et al. A human cell-surface glycoprotein that carries Cromer-related blood group antigens on erythrocytes and is also expressed on leucocytes and platelets. Immunology 1987; 62:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/47\">",
"      Rao N, Whitsett CF, Oxendine SM, Telen MJ. Human erythrocyte acetylcholinesterase bears the Yta blood group antigen and is reduced or absent in the Yt(a-b-) phenotype. Blood 1993; 81:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/48\">",
"      Spring FA, Gardner B, Anstee DJ. Evidence that the antigens of the Yt blood group system are located on human erythrocyte acetylcholinesterase. Blood 1992; 80:2136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/49\">",
"      Bobolis KA, Moulds JJ, Telen MJ. Isolation of the JMH antigen on a novel phosphatidylinositol-linked human membrane protein. Blood 1992; 79:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/50\">",
"      Smith C, Gasparetto C, Collins N, et al. Purification and partial characterization of a human hematopoietic precursor population. Blood 1991; 77:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/51\">",
"      Terstappen LW, Nguyen M, Lazarus HM, Medof ME. Expression of the DAF (CD55) and CD59 antigens during normal hematopoietic cell differentiation. J Leukoc Biol 1992; 52:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/52\">",
"      Terstappen LW, Nguyen M, Huang S, et al. Defective and normal haematopoietic stem cells in paroxysmal nocturnal haemoglobinuria. Br J Haematol 1993; 84:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/53\">",
"      Gasparetto C, Smith C, Gillio A, et al. Enrichment of peripheral blood stem cells in a primate model following administration of a single dose of rh-IL-1 beta. Bone Marrow Transplant 1994; 14:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/54\">",
"      Huan SD, Hester J, Spitzer G, et al. Influence of mobilized peripheral blood cells on the hematopoietic recovery by autologous marrow and recombinant human granulocyte-macrophage colony-stimulating factor after high-dose cyclophosphamide, etoposide, and cisplatin. Blood 1992; 79:3388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/55\">",
"      Prince GM, Nguyen M, Lazarus HM, et al. Peripheral blood harvest of unaffected CD34+ CD38- hematopoietic precursors in paroxysmal nocturnal hemoglobinuria. Blood 1995; 86:3381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/56\">",
"      Nakakuma H, Kawaguchi T, Horikawa K, et al. Proposal for a classification of the clinical stages of paroxysmal nocturnal hemoglobinuria. Blood 1995; 86:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/57\">",
"      Hoffmann EM. Inhibition of complement by a substance isolated from human erythrocytes. II. Studies on the site and mechanism of action. Immunochemistry 1969; 6:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/58\">",
"      Fujioka S, Yamada T. Varying populations of CD59-negative, partly positive, and normally positive blood cells in different cell lineages in peripheral blood of paroxysmal nocturnal hemoglobinuria patients. Am J Hematol 1994; 45:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/59\">",
"      Ohashi H, Hotta T, Ichikawa A, et al. Peripheral blood cells are predominantly chimeric of affected and normal cells in patients with paroxysmal nocturnal hemoglobinuria: simultaneous investigation on clonality and expression of glycophosphatidylinositol-anchored proteins. Blood 1994; 83:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/60\">",
"      Plesner T, Hansen NE, Carlsen K. Estimation of PI-bound proteins on blood cells from PNH patients by quantitative flow cytometry. Br J Haematol 1990; 75:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/61\">",
"      Shichishima T, Terasawa T, Saitoh Y, et al. Diagnosis of paroxysmal nocturnal haemoglobinuria by phenotypic analysis of erythrocytes using two-colour flow cytometry with monoclonal antibodies to DAF and CD59/MACIF. Br J Haematol 1993; 85:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/62\">",
"      Nishimura Ji J, Hirota T, Kanakura Y, et al. Long-term support of hematopoiesis by a single stem cell clone in patients with paroxysmal nocturnal hemoglobinuria. Blood 2002; 99:2748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/63\">",
"      Araten DJ, Nafa K, Pakdeesuwan K, Luzzatto L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci U S A 1999; 96:5209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/64\">",
"      Wang H, Chuhjo T, Yasue S, et al. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood 2002; 100:3897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/65\">",
"      Sugimori C, Mochizuki K, Qi Z, et al. Origin and fate of blood cells deficient in glycosylphosphatidylinositol-anchored protein among patients with bone marrow failure. Br J Haematol 2009; 147:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/66\">",
"      Rosse WF, Adams JP, Thorpe AM. The population of cells in paroxysmal nocturnal haemoglobinuria of intermediate sensitivity to complement lysis: significance and mechanism of increased immune lysis. Br J Haematol 1974; 28:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/67\">",
"      Sloand EM, Mainwaring L, Keyvanfar K, et al. Transfer of glycosylphosphatidylinositol-anchored proteins to deficient cells after erythrocyte transfusion in paroxysmal nocturnal hemoglobinuria. Blood 2004; 104:3782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/68\">",
"      Navenot JM, Muller JY, Blanchard D. Investigation of the survival of paroxysmal nocturnal hemoglobinuria red cells through the immunophenotyping of reticulocytes. Transfusion 1998; 38:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/69\">",
"      Kooyman DL, Byrne GW, McClellan S, et al. In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science 1995; 269:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/70\">",
"      Ware RE, Rosse WF, Hall SE. Immunophenotypic analysis of reticulocytes in paroxysmal nocturnal hemoglobinuria. Blood 1995; 86:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/71\">",
"      Bessler M, Hillmen P, Longo L, et al. Genomic organization of the X-linked gene (PIG-A) that is mutated in paroxysmal nocturnal haemoglobinuria and of a related autosomal pseudogene mapped to 12q21. Hum Mol Genet 1994; 3:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/72\">",
"      Nagarajan S, Brown CJ, Medof ME. Identification of a PIG-A related processed gene on chromosome 12. Hum Genet 1995; 95:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/73\">",
"      Brubaker LH, Essig LJ, Mengel CE. Neutrophil life span in paroxysmal nocturnal hemoglobinuria. Blood 1977; 50:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/74\">",
"      Rosse WF. The life-span of complement-sensitive and -insensitive red cells in paroxysmal nocturnal hemoglobinuria. Blood 1971; 37:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/75\">",
"      Schubert J, Uciechowski P, Delany P, et al. The PIG-anchoring defect in NK lymphocytes of PNH patients. Blood 1990; 76:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/76\">",
"      Tseng JE, Hall SE, Howard TA, Ware RE. Phenotypic and functional analysis of lymphocytes in paroxysmal nocturnal hemoglobinuria. Am J Hematol 1995; 50:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/77\">",
"      Richards SJ, Norfolk DR, Swirsky DM, Hillmen P. Lymphocyte subset analysis and glycosylphosphatidylinositol phenotype in patients with paroxysmal nocturnal hemoglobinuria. Blood 1998; 92:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/78\">",
"      Hillmen P, Lewis SM, Bessler M, et al. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/79\">",
"      Nakakuma H, Nagakura S, Kawaguchi T, et al. Persistence of affected T lymphocytes in long-term clinical remission in paroxysmal nocturnal hemoglobinuria. Blood 1994; 84:3925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/80\">",
"      Schubert J, Uciechowski P, Zielinska-Skowronek M, et al. Differences in activation of normal and glycosylphosphatidylinositol-negative lymphocytes derived from patients with paroxysmal nocturnal hemoglobinuria. J Immunol 1992; 148:3814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/81\">",
"      Tomiyama J, Ninomiya H, Abe T. Enhanced complement-susceptibility and dysfunction of lymphocytes in paroxysmal nocturnal haemoglobinuria (PNH). Br J Haematol 1990; 76:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/82\">",
"      Schubert J, Stroehmann A, Scholz C, Schmidt RE. Glycosylphosphatidylinositol (GPI)-anchored surface antigens in the allogeneic activation of T cells. Clin Exp Immunol 1995; 102:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/83\">",
"      Kwong YL, Lee CP, Chan TK, Chan LC. Flow cytometric measurement of glycosylphosphatidyl-inositol-linked surface proteins on blood cells of patients with paroxysmal nocturnal hemoglobinuria. Am J Clin Pathol 1994; 102:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/84\">",
"      Kawakami Z, Ninomiya H, Tomiyama J, Abe T. Deficiency of glycosyl-phosphatidylinositol anchored proteins on paroxysmal nocturnal haemoglobinuria (PNH) neutrophils and monocytes: heterogeneous deficiency of decay-accelerating factor (DAF) and CD16 on PNH neutrophils. Br J Haematol 1990; 74:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/85\">",
"      Melillo LM, Cascavilla N, Musto P, et al. Increased CD10/TdT positive cells in the bone marrow of an infant with immune thrombocytopenia. Haematologica 1994; 79:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/86\">",
"      Aster RH, Enright SE. A platelet and granulocyte membrane defect in paroxysmal nocturnal hemoglobinuria: usefulness for the detection of platelet antibodies. J Clin Invest 1969; 48:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/87\">",
"      Savage WJ, Barber JP, Mukhina GL, et al. Glycosylphosphatidylinositol-anchored protein deficiency confers resistance to apoptosis in PNH. Exp Hematol 2009; 37:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/88\">",
"      Brown D. Structure and function of membrane rafts. Int J Med Microbiol 2002; 291:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/89\">",
"      Szpurka H, Schade AE, Jankowska AM, Maciejewski JP. Altered lipid raft composition and defective cell death signal transduction in glycosylphosphatidylinositol anchor-deficient PIG-A mutant cells. Br J Haematol 2008; 142:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13593/abstract/90\">",
"      Suzuki T, Kiyokawa N, Taguchi T, et al. CD24 induces apoptosis in human B cells via the glycolipid-enriched membrane domains/rafts-mediated signaling system. J Immunol 2001; 166:5567.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7156 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-8641F3AC89-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_17_13593=[""].join("\n");
var outline_f13_17_13593=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13962299\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MISSING PROTEINS IN PNH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Alkaline phosphatase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Acetylcholinesterase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Decay accelerating factor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Importance of CD59",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Missing blood group antigens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DEFICIENCY OF GPI-LINKED PROTEINS IN BLOOD CELLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hematopoietic progenitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Peripheral blood cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - PNH cells in other conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Erythrocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Granulocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Lymphocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Monocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Platelets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5857834\">",
"      GPI-linked proteins and apoptosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13962299\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/586?source=related_link\">",
"      Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29930?source=related_link\">",
"      Aplastic anemia: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14121?source=related_link\">",
"      Clinical manifestations of paroxysmal nocturnal hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=related_link\">",
"      Complement pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17082?source=related_link\">",
"      Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42392?source=related_link\">",
"      Pathogenesis of paroxysmal nocturnal hemoglobinuria: Absence of the GPI anchor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10854?source=related_link\">",
"      Regulators and receptors of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=related_link\">",
"      Treatment of intermediate, low, or very low risk myelodysplastic syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_17_13594="Evaluation and treatment of membranoproliferative glomerulonephritis";
var content_f13_17_13594=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and treatment of membranoproliferative glomerulonephritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/17/13594/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/17/13594/contributors\">",
"     Fernando C Fervenza, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/17/13594/contributors\">",
"     Sanjeev Sethi, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/17/13594/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/17/13594/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/17/13594/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/17/13594/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/17/13594/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Membranoproliferative glomerulonephritis (MPGN), also known as mesangiocapillary glomerulonephritis, is a pattern of glomerular injury viewed by light microscopy. Its name is derived from the characteristic histologic changes including hypercellularity and thickening of the glomerular basement membrane, often leading to a lobular appearance of the glomerular tuft (",
"    <a class=\"graphic graphic_picture graphicRef67999 graphicRef78967 \" href=\"UTD.htm?39/57/40858\">",
"     picture 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=see_link\">",
"     \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of MPGN depends upon the underlying cause as most patients have either a circulating immune complex disease or dysregulation of the alternative complement pathway. These issues will be reviewed here with the exception of MPGN due to dense deposit disease. The treatment of patients with dense deposit disease and recurrence of MPGN after kidney transplantation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3498?source=see_link\">",
"     \"Dense deposit disease (membranoproliferative glomerulonephritis type II)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32614?source=see_link\">",
"     \"Membranoproliferative glomerulonephritis: Recurrence after transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H267198035\">",
"    <span class=\"h1\">",
"     PATHOLOGIC CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Membranoproliferative glomerulonephritis (MPGN) was originally classified according to the findings on electron microscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=see_link&amp;anchor=H559999613#H559999613\">",
"     \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\", section on 'Classification based upon electron microscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I is characterized by discrete immune deposits in the mesangium and subendothelial space, similar to that seen in lupus nephritis (",
"      <a class=\"graphic graphic_picture graphicRef64411 \" href=\"UTD.htm?8/37/8793\">",
"       picture 2",
"      </a>",
"      ). The deposits are thought to reflect the deposition of circulating immune complexes.",
"     </li>",
"     <li>",
"      Type II (also called dense deposit disease) is characterized by continuous, dense ribbon-like deposits along the basement membranes of the glomeruli, tubules, and Bowman's capsule (",
"      <a class=\"graphic graphic_picture graphicRef73319 \" href=\"UTD.htm?24/19/24883\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Type III is characterized by subepithelial deposits in addition to deposits in the mesangium and subendothelial space. There is complex disruption of the glomerular basement membrane with large lucent areas (",
"      <a class=\"graphic graphic_picture graphicRef77236 \" href=\"UTD.htm?34/8/34953\">",
"       picture 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, there are limitations to this classification and we prefer a classification based upon immunofluorescence microscopy, as described in detail elsewhere and in the next section [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=see_link&amp;anchor=H92986221#H92986221\">",
"     \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\", section on 'Limitations of this classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1655349110\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes and evaluation of membranoproliferative glomerulonephritis (MPGN) differ in immune complex-mediated and complement-mediated disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=see_link&amp;anchor=H981933439#H981933439\">",
"     \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\", section on 'Classification based upon immunofluorescence microscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20702942\">",
"    <span class=\"h2\">",
"     Immune complex-mediated MPGN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune complex-mediated MPGN is characterized by positive staining for immunoglobulin and complement on immunofluorescence microscopy. Patients who have such findings should be evaluated for the following disorders",
"    <strong>",
"     before",
"    </strong>",
"    treatment for MPGN is initiated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=see_link&amp;anchor=H455985606#H455985606\">",
"     \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\", section on 'Immune complex-mediated MPGN'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infections &mdash; A variety of infections can lead to MPGN. Hepatitis B and hepatitis C virus should be excluded by serology, while chronic bacterial infections should be excluded by culture, including blood cultures. We do not test for fungi in the absence of a suggestive history (eg, fever of unknown origin, unexplained pulmonary infiltrates) or for parasitic infections (eg, malaria, schistosomiasis, leishmaniasis) unless the patient resides in or has visited an endemic site. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=see_link\">",
"       \"Serologic diagnosis of hepatitis B virus infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link\">",
"       \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Autoimmune diseases &mdash; Autoimmune diseases that have been associated with MPGN include systemic lupus erythematosus and rarely Sj&ouml;gren syndrome and systemic sclerosis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/3-6\">",
"       3-6",
"      </a>",
"      ]. Such patients almost always have manifestations of the underlying disease and other than serologic testing for lupus, we would not evaluate for Sj&ouml;gren syndrome and systemic sclerosis in the absence of suggestive manifestations. The specific evaluation of these disorders is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27706?source=see_link&amp;anchor=H11#H11\">",
"       \"Diagnosis and classification of renal disease in systemic lupus erythematosus\", section on 'Diffuse lupus nephritis (class IV)'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=see_link\">",
"       \"Diagnosis and differential diagnosis of systemic lupus erythematosus in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link\">",
"       \"Classification and diagnosis of Sj&ouml;gren's syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=see_link&amp;anchor=H14#H14\">",
"       \"Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults\", section on 'Renal disease'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43095?source=see_link\">",
"       \"Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Monoclonal gammopathy &mdash; Monoclonal gammopathies should be excluded by serum protein electrophoresis or serum free light chains and urine electrophoresis and immunofixation. Most patients with MPGN and a monoclonal gammopathy have no identifiable disease; this disorder has been called MPGN associated with monoclonal gammopathy of uncertain significance (MGUS). In a report from the Mayo Clinic of 68 patients with MPGN who were not infected with hepatitis C virus, 28 (41 percent) had a monoclonal gammopathy on serum",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      urine electrophoresis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/7\">",
"       7",
"      </a>",
"      ]. Most of these patients had no identifiable underlying disease and were considered to have monoclonal gammopathy of undetermined significance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=see_link\">",
"       \"Diagnosis of monoclonal gammopathy of undetermined significance\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      However, occasional patients with a monoclonal gammopathy and MPGN have a serious and potentially treatable cause. These include multiple myeloma, low-grade B cell lymphoma, and chronic lymphocytic leukemia [",
"      <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/7-10\">",
"       7-10",
"      </a>",
"      ]. These disorders may be diagnosed at presentation or later after an initial diagnosis of monoclonal gammopathy of undetermined significance [",
"      <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/10\">",
"       10",
"      </a>",
"      ]. As described below, treatment of these disorders can lead to improvement in the MPGN. (See",
"      <a class=\"local\" href=\"#H56342434\">",
"       'Treatment of the underlying cause'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20702949\">",
"    <span class=\"h2\">",
"     Complement-mediated MPGN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complement-mediated MPGN is characterized by positive staining for C3 and no staining for immunoglobulin by immunofluorescence microscopy (",
"    <a class=\"graphic graphic_picture graphicRef76040 \" href=\"UTD.htm?22/12/22727\">",
"     picture 5",
"    </a>",
"    ). Such patients should undergo an evaluation for activation of the alternative pathway of complement. We suggest measuring C3, C4, CH50 (which provides a measure of activation of the classic complement pathway), and AH50 (which provides a measure of activation of the alternative complement pathway). Low or absent levels should lead to genetic analysis for mutations and allele variants of complement factors and to assays for autoantibodies to complement regulating proteins (eg, factors H and I), including testing for C3 nephritic factor (C3NeF) and, if available, serum levels of the membrane attack complex. Factor H and other measurements, including C3 activation and breakdown products, C3NeF, and mutation screening of a variety of complement related genes including factor H are available in select research laboratories (",
"    <a class=\"graphic graphic_table graphicRef57107 \" href=\"UTD.htm?33/63/34812\">",
"     table 1",
"    </a>",
"    ). Normal C3 levels does not rule out a complement-mediated MPGN [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\", section on 'Complement-mediated MPGN'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3498?source=see_link&amp;anchor=H12#H12\">",
"     \"Dense deposit disease (membranoproliferative glomerulonephritis type II)\", section on 'Special diagnostic tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56342427\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three components to the treatment of membranoproliferative glomerulonephritis (MPGN): treatment of the underlying cause of the MPGN, if possible (eg, infection); assessment of the factors that predict renal prognosis; and treatment of the MPGN, mostly with immunosuppressive drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56342434\">",
"    <span class=\"h2\">",
"     Treatment of the underlying cause",
"    </span>",
"    &nbsp;&mdash;&nbsp;When an inciting condition is present (eg, infection), resolution of the MPGN usually occurs after successful treatment of the primary disease, such as antiviral therapy in MPGN due to hepatitis C or B virus. Immunosuppressive therapy is both",
"    <strong>",
"     unnecessary and potentially deleterious",
"    </strong>",
"    in patients with hepatitis, except in selected conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=see_link&amp;anchor=H7#H7\">",
"     \"Renal disease associated with hepatitis C virus infection\", section on 'Diagnosis and treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44488?source=see_link&amp;anchor=H7#H7\">",
"     \"Renal disease associated with hepatitis B virus infection\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36682?source=see_link\">",
"     \"Treatment of the mixed cryoglobulinemia syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At least partial remission of MPGN can also be induced with early antimicrobial therapy of bacterial endocarditis or an infected ventriculoatrial shunt [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/14\">",
"     14",
"    </a>",
"    ], chemotherapy in chronic lymphocytic leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/8,15\">",
"     8,15",
"    </a>",
"    ], and treatment of multiple myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/16\">",
"     16",
"    </a>",
"    ]. In addition, among patients with MPGN and MGUS, some patients progress to a malignancy such as multiple myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal therapy of MPGN in patients with a monoclonal gammopathy of undetermined significance (MGUS) is uncertain. We suggest treating patients with a non-IgM MGUS with a regimen used to treat multiple myeloma. In patients with an IgM MGUS, we suggest a regimen used to treat Waldenstrom macroglobulinemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link\">",
"     \"Determination of initial therapy in patients with multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37626?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment and prognosis of Waldenstr&ouml;m macroglobulinemia\", section on 'Initial treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56342453\">",
"    <span class=\"h2\">",
"     Predictors of renal prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other glomerular diseases, patients who present with non-nephrotic proteinuria (less than 3.5",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    no hypoalbuminemia, and no edema), normal serum creatinine or estimated glomerular filtration rate, and normal blood pressure have a benign prognosis as long as the renal manifestations do not become more prominent. Poor prognostic signs at presentation include the nephrotic syndrome, an elevated serum creatinine, hypertension (or blood pressure well above the patient&rsquo;s previous baseline), and, on renal biopsy, crescents [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/17-21\">",
"     17-21",
"    </a>",
"    ]. In contrast, patients with non-nephrotic proteinuria and normal blood pressure appear to have an excellent long-term renal prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/18,21\">",
"     18,21",
"    </a>",
"    ]. Greater degrees of hematuria (eg, 50 or more versus 5 to 20 red blood cells per high power field) suggest more inflammation but there is no evidence of an independent effect on prognosis. (See",
"    <a class=\"local\" href=\"#H267197965\">",
"     'Suggested regimens according to presentation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Another important adverse prognostic sign on renal biopsy is tubulointerstitial disease (interstitial inflammation, fibrosis, and tubular atrophy) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/20\">",
"     20",
"    </a>",
"    ]. The risk of progression usually correlates more closely with the severity of the tubulointerstitial injury than with the degree of glomerular damage. This finding is typical of most glomerular diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=see_link&amp;anchor=H7#H7\">",
"     \"Secondary factors and progression of chronic kidney disease\", section on 'Tubulointerstitial fibrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Older reports suggested a relatively poor renal prognosis in patients with apparently idiopathic MPGN [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/18-20,22,23\">",
"     18-20,22,23",
"    </a>",
"    ]. However, such reports should be interpreted with caution since they were compiled before our knowledge of the many treatable disorders that can underlie MPGN. These include hepatitis C virus infection, monoclonal gammopathies, and complement cascade abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/24\">",
"     24",
"    </a>",
"    ]. The net effect is that a possible underlying etiology is likely to be found in the majority of cases of MPGN; idiopathic disease is now uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H858669072\">",
"    <span class=\"h2\">",
"     Treatment of the glomerulonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of secondary MPGN is directed at treatment of the underlying condition since the renal disease often resolves with treatment of causes such as infection, autoimmune disorders, and monoclonal gammopathy.",
"   </p>",
"   <p>",
"    Once treatable underlying causes of MPGN have been excluded, three conditions remain:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Idiopathic immune complex-mediated MPGN",
"     </li>",
"     <li>",
"      C3 glomerulonephritis",
"     </li>",
"     <li>",
"      Dense deposit disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H284123153\">",
"    <span class=\"h3\">",
"     Idiopathic immune complex-mediated MPGN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of idiopathic immune complex-complex mediated MPGN has not been well defined. The best data come from a series of 126 patients, 93 of whom were evaluated for hepatitis C and B virus and a dysproteinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/7\">",
"     7",
"    </a>",
"    ]. Among these patients, 40 (43 percent) did not have hepatitis C or B virus infection or a dysproteinemia.",
"   </p>",
"   <p>",
"    There are no randomized trials upon which to base treatment recommendations for patients with idiopathic immune complex-mediated MPGN in whom hepatitis C and monoclonal gammopathy have been excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/1\">",
"     1",
"    </a>",
"    ]. Treatment is generally determined by the severity of kidney dysfunction. Patients who have a normal estimated GFR and non-nephrotic range proteinuria may be treated conservatively with angiotensin inhibitors alone in order to control blood pressure and reduce proteinuria, since the long-term outcome is relatively benign in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. These patients should be seen at three and six months to detect possible disease progression (eg, increases in serum creatinine or proteinuria as estimated from the urine protein-to-creatinine ratio) due to continuing immune injury. If there is no disease progression at six months, subsequent visits are at six month intervals if the patient remains asymptomatic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H11#H11\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Effect of renin-angiotensin system inhibitors on progression of CKD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182574437\">",
"    <span class=\"h4\">",
"     Immunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for immunosuppressive therapy include nephrotic range proteinuria, a reduced estimated glomerular filtration,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe histologic changes on renal biopsy (eg, crescents) at baseline, and progressive disease over time with angiotensin inhibitors alone (not including the acute, hemodynamically-mediated rise in serum creatinine that may be induced by angiotensin inhibition and typically occurs soon after the onset of therapy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H74959533#H74959533\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal immunosuppressive therapy for idiopathic immune complex-mediated MPGN is not known since there are few randomized trials. Early reports should be interpreted with caution since historical controls were used, the statistical significance was marginal,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the power to detect substantial differences was small [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/22,27\">",
"     22,27",
"    </a>",
"    ]. In addition, early studies were performed before angiotensin inhibitors were commonly used, and the diagnosis of idiopathic MPGN was made before investigators were as aware of such causes as hepatitis C virus infection, monoclonal gammopathies, and complement pathway abnormalities that underlie MPGN [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=see_link\">",
"     \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All of the randomized trials and observational studies described below used the electron microscopy classification of MPGN (types I and III, type II [dense deposit disease] is discussed separately). Although we prefer a classification based upon immunofluorescence microscopy, as mentioned above, there are only limited data evaluating the efficacy of immunosuppressive therapies according to this classification [",
"      <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H267198035\">",
"       'Pathologic classification'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=see_link\">",
"       \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3498?source=see_link&amp;anchor=H15#H15\">",
"       \"Dense deposit disease (membranoproliferative glomerulonephritis type II)\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Occasional patients with indolent disease present late in the course at a time when active inflammation has subsided. Such patients may have a bland urine sediment with a variable degree of proteinuria and elevation in serum creatinine. These patients are also treated with angiotensin inhibitors alone unless the renal biopsy shows signs of active inflammation. Patients who present with advanced renal insufficiency and severe tubulointerstitial fibrosis of renal biopsy are less likely to benefit from immunosuppressive therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H267197965\">",
"    <span class=\"h5\">",
"     Suggested regimens according to presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of immunosuppressive therapies have been tried in patients with MPGN including glucocorticoids alone or with cytoxic agents, and calcineurin inhibitors. As mentioned above, the major risk factors for an adverse renal prognosis are nephrotic syndrome, an elevated serum creatinine, and hypertension (or blood pressure well above the patient&rsquo;s previous baseline). (See",
"    <a class=\"local\" href=\"#H56342453\">",
"     'Predictors of renal prognosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Our approach is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Non-nephrotic proteinuria (less than 3.5",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      no hypoalbuminemia, and no edema), normal serum creatinine or estimated glomerular filtration rate, and normal blood pressure (mild disease) &mdash; We suggest conservative therapy with angiotensin inhibition alone; there is no evidence of benefit from immunosuppressive in these patients. Studies in children with MPGN, non-nephrotic proteinuria, and normal blood pressure have shown excellent long-term outcomes whether or not the patients were treated with glucocorticoids [",
"      <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/21\">",
"       21",
"      </a>",
"      ]. However, disease progression can occur. As a result, regular monitoring of the serum creatinine, urine protein-to-creatinine ratio, and the urinalysis is warranted. Although supportive data are not available, patients with more hematuria (eg, 50 or more versus 5 to 20 red blood cells per high power field) may be at greater risk for progressive disease. We suggest that patients with more hematuria be monitored more frequently.",
"     </li>",
"     <li>",
"      Nephrotic syndrome, normal or near normal creatinine &mdash; We suggest a treatment regimen similar to that used in focal segmental glomerulosclerosis, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (maximum dose 60 to 80",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for 12 to 16 weeks. If the patient responds, prednisone is gradually tapered to alternate day therapy over six to eight months. If there is less than a 30 percent reduction in proteinuria after 12 to 16 weeks, we recommend tapering and discontinuation of prednisone. We initiate angiotensin inhibition therapy at the same time. Calcineurin inhibitors may be considered in patients who do not respond to or tolerate glucocorticoids. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34714?source=see_link&amp;anchor=H12#H12\">",
"       \"Treatment of primary focal segmental glomerulosclerosis\", section on 'Prednisone dose'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Elevated serum creatinine, with or without nephrotic syndrome",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypertension, and without crescents &mdash; We suggest initial therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, maximum dose 60 to 80",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      If there is no response or there are increases in the serum creatinine",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      proteinuria, we would add",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, reduced to 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in patients with a serum creatinine greater than 2.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [221",
"      <span class=\"nowrap\">",
"       micromol/L]",
"      </span>",
"      or age greater than 60 years) for three to six months. In patients with persistent disease activity despite cyclophosphamide, we suggest cessation of cyclophosphamide and a trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H267200721\">",
"       'Rituximab'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Rapidly progressive disease with or without crescents &mdash; We recommend that patients with rapidly progressive crescentic MPGN be treated with glucocorticoids and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      using the regimen described elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18231?source=see_link&amp;anchor=H11#H11\">",
"       \"Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This approach is based upon studies of the efficacy of different immunosuppressive drugs in the treatment of MPGN, as described in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h5\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are widely used in the treatment of MPGN, both as monotherapy and in combination with other immunosuppressive drugs. This section will review the evidence supporting efficacy with monotherapy.",
"   </p>",
"   <p>",
"    A benefit from long-term alternate-day glucocorticoid therapy for idiopathic MPGN in children was demonstrated in a randomized controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/28\">",
"     28",
"    </a>",
"    ] and several observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. The best data are provided by a trial performed by the International Study of Kidney Disease in Children in which 80 children (mean age 10 years) with nephrotic range proteinuria but preserved renal function (GFR &ge;70",
"    <span class=\"nowrap\">",
"     ml/min",
"    </span>",
"    per 1.73 m2) were randomly assigned to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or lactose, 40",
"    <span class=\"nowrap\">",
"     mg/m2,",
"    </span>",
"    every other day for a mean duration of 41 months [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/28\">",
"     28",
"    </a>",
"    ]. At entry, the mean GFR was 110",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2, the mean serum creatinine was 0.75",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (66",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    and mean protein excretion was 118",
"    <span class=\"nowrap\">",
"     mg/h",
"    </span>",
"    per 1.73m2. Treatment failure was defined as an increase in baseline serum creatinine of more than 30 percent or more than 0.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (35",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    therapy was associated with the following benefits: a significantly lower rate of treatment failure (40 versus 55 percent) and an almost significant increase in the rate of stable renal function at 10 years (61 versus 12 percent, p = 0.07). The benefit of prednisone was partially offset by its toxicity, particularly hypertension which led to cessation of therapy in five patients treated with prednisone (three developed hypertensive encephalopathy) compared with two patients treated with lactose (both developed hypertensive encephalopathy). Because more patients were treated with prednisone than lactose (47 versus 33), the frequency of cessation of therapy for hypertension was similar in both groups (6.4 versus 6.1 percent), which reflects the importance of hypertension in the natural history of the disease.",
"   </p>",
"   <p>",
"    There are a number of problems that limit the interpretation of this trial for current therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patients were enrolled between 1970 and 1980, before patients with MPGN were routinely evaluated for hepatitis C and B or abnormalities in the complement cascade. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=see_link\">",
"       \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The patients in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      group had a much shorter duration of disease (9 versus 18 months) which may have overestimated the benefit of prednisone.",
"     </li>",
"     <li>",
"      The benefit of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      was not observed until after 90 months of follow-up, when a limited number of patients were available for observation (11 patients in the prednisone-treated group and 7 patients in the lactose group).",
"     </li>",
"     <li>",
"      The inclusion of patients with dense deposit disease (MPGN type II) may have resulted in an underestimate of the benefit of glucocorticoids. Among patients with MPGN type I or III, treatment failure was much lower with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      compared with lactose (33 versus 58 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In children, the response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    may vary with the MPGN type based upon electron microscopy findings. This was suggested in a retrospective study that evaluated the outcome of 21 and 25 children with type I and type III disease, respectively, all of whom were treated with alternate-day prednisone (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    to a maximum of 80 mg every other day) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/32\">",
"     32",
"    </a>",
"    ]. At follow-up at a minimum of five years, the glomerular filtration rate of patients with type I and type III disease had slightly increased and markedly decreased, respectively (plus 6.3 versus minus 34.8",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2, respectively). The patients with type III disease also had significantly more relapses. Many patients labeled as having MPGN type III when this study was performed may have had unrecognized C3 glomerulonephritis. (See",
"    <a class=\"local\" href=\"#H267198035\">",
"     'Pathologic classification'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H284123283\">",
"     'C3 glomerulonephritis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Randomized trials of glucocorticoid therapy in idiopathic MPGN in adults have not been performed. Retrospective studies have not shown a clear benefit, although treatment was not as prolonged as in children [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. This is potentially important since, in the randomized trial in children described above, significant benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy compared with placebo was not observed until after 90 months of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A separate issue is the role of pulse intravenous glucocorticoid therapy rather than conventional oral therapy. Pulse therapy is almost always used as part of initial therapy in patients with crescentic glomerulonephritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18231?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulse therapy has also been evaluated in less severe forms of MPGN, primarily in children [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. The best data comparative data come from an observational study of 19 children with MPGN type I; 11 were treated initially with pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    and 8 with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/33\">",
"     33",
"    </a>",
"    ]. At presentation, the two groups had similar clinical, laboratory, and histopathologic features. The treatment regimen was intravenous pulse methylprednisolone (30",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    maximum 1.5) given on alternate days for six doses followed by single-dose alternate day oral prednisone (2",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    maximum 60 mg). Therapy was stopped after two years if the disease was clinically stable.",
"   </p>",
"   <p>",
"    Twelve patients completed eight years of follow-up. The frequency of progression to end-stage renal disease was one in seven with pulse therapy versus four of five with oral therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H267200713\">",
"    <span class=\"h5\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of cytotoxic agents in the treatment of MPGN has not been clearly demonstrated.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    has been the most widely studied. Data are limited on other cytotoxic drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the only randomized trial, 59 patients with MPGN were assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    or to no specific therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/36\">",
"     36",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    Entry criteria included MPGN type I or type II (dense deposit disease) plus a corrected creatinine clearance less than 80",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per1.73 m2",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    protein excretion greater than 2",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=see_link&amp;anchor=H559999613#H559999613\">",
"     \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\", section on 'Classification based upon electron microscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At two years, there was no difference in actuarial survival between the treatment and the control groups at two years. There was no significant difference between groups in the rate of decline of renal function or in proteinuria. However, the study was underpowered to determine if this treatment might be beneficial.",
"   </p>",
"   <p>",
"    In an observational study, 19 patients with MPGN were treated with a regimen that consisted of four phases: (1) induction with intravenous pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    orally; (2) maintenance with alternate-day oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and daily cyclophosphamide; (3) tapering during which prednisone alone was slowly decreased; (4) discontinuation when cyclophosphamide was stopped and prednisone slowly withdrawn [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/37\">",
"     37",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    At the end of the treatment that lasted on average 10 months, 15 patients entered complete remission, 3 patients had a partial remission, and 1 patient progressed. There were eight relapses in six patients: four in three patients were retreated and remitted completely. Four patients who had relapsed after 4, 8, 11, and 13 years of remission refused retreatment and progressed rapidly to end-stage renal disease.",
"   </p>",
"   <p>",
"    In addition to these observations,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    along with pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    and oral glucocorticoids is the routine regimen for most causes of rapidly progressive (crescentic) glomerulonephritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18231?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H267200721\">",
"    <span class=\"h5\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    has been effective in the treatment of MPGN associated with chronic lymphocytic leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/15,38,39\">",
"     15,38,39",
"    </a>",
"    ]. No serious adverse effects were noted. However, in these patients, it is unclear if the benefit was due to a direct effect on MPGN or to treatment of the leukemia. (See",
"    <a class=\"local\" href=\"#H56342434\">",
"     'Treatment of the underlying cause'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of relapsed or refractory chronic lymphocytic leukemia\", section on 'Rituximab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6362?source=see_link&amp;anchor=H5622422#H5622422\">",
"     \"Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia\", section on 'Fludarabine-based therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in patients without underlying leukemia was evaluated in six adults with MPGN type I; the MPGN was idiopathic in four and associated with cryoglobulinemia in two [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/40\">",
"     40",
"    </a>",
"    ]. The patients had no known cause of MPGN (see",
"    <a class=\"local\" href=\"#H56342434\">",
"     'Treatment of the underlying cause'",
"    </a>",
"    above). The rituximab dose was 1000 mg intravenously on days 1 and 15; the patients were followed for one year. The mean serum creatinine was 1.7 mg dL (150",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    at baseline. The primary outcome was the change in proteinuria from baseline (mean 3.9",
"    <span class=\"nowrap\">",
"     g/day).",
"    </span>",
"    Protein excretion fell at all time points with a mean minimum of 1.4",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    at nine months. There was no change in creatinine clearance and there were no adverse effects.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    has also led to long-lasting complete or partial remissions in seven of eight patients with MPGN associated with a monoclonal gammopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/10\">",
"     10",
"    </a>",
"    ]. Some had underlying myeloma or lymphoma and some had monoclonal gammopathy of undetermined significance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4041?source=see_link\">",
"     \"Clinical course and management of monoclonal gammopathy of undetermined significance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20875950\">",
"    <span class=\"h5\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are only limited data from small observational studies that have evaluated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF), typically given with oral glucocorticoids in patients with MPGN [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. One observational study in adults included five patients who were treated with MMF and oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    and six who were not treated with immunosuppressive agents [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/41\">",
"     41",
"    </a>",
"    ]. The initial MMF dose was 500",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    which was increased gradually to 2000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or until remission of proteinuria was achieved; the average drugs dose was 1100",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    The initial prednisolone dose was 60",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    tapered to 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    within two months and withdrawn at one year.",
"   </p>",
"   <p>",
"    At 18 months, proteinuria fell from 5.1 to 2.6",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    in the MMF group compared with no change in proteinuria in patients who were not treated. In addition, the creatinine clearance increased significantly in the MMF group (103 to 159",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    and fell significantly in the control group (108 to 67",
"    <span class=\"nowrap\">",
"     mL/min).",
"    </span>",
"    The relative contribution of MMF and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    could not be ascertained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H267200942\">",
"    <span class=\"h5\">",
"     Calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited uncontrolled data suggest calcineurin inhibitors reduce proteinuria in some patients with MPGN [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. In one report, for example, 18 patients who were resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    glucocorticoids were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    plus low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/44\">",
"     44",
"    </a>",
"    ]. At an average follow up of two years, all but one patient achieved complete or partial remission of proteinuria. Only one patient relapsed following discontinuation of cyclosporine. Benefit has also been suggested with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h4\">",
"     Antiplatelet agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    has been evaluated in adults with idiopathic MPGN. The rationale for the use of these drugs is that platelet consumption is increased in MPGN, suggesting a possible etiologic role for platelets in the glomerular injury. Neither of the following trials screened for or excluded patients infected with hepatitis C virus or abnormalities in the complement cascade.",
"   </p>",
"   <p>",
"    In a randomized trial, 41 patients with MPGN type I were treated for one year with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    (225",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , 975",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/48\">",
"     48",
"    </a>",
"    ]. The rate of decline in GFR (as determined by iothalamate clearance) was markedly reduced in the treatment group (1.3 versus 19.6",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2). In addition, fewer patients in the treatment group progressed to end-stage renal disease at three to five years (14 versus 47 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=see_link&amp;anchor=H559999613#H559999613\">",
"     \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\", section on 'Classification based upon electron microscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The beneficial effect was independent of changes in proteinuria, hematuria, or complement profile. Bleeding complications led to discontinuation of treatment in 15 percent of patients. Reevaluation of this cohort found no difference in outcome at 10 years, suggesting that prolonged antiplatelet therapy may be required if the benefit is to be sustained [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The possible necessity for prolonged therapy is consistent with the findings in a subsequent randomized trial of 18 patients with MPGN (three of whom had dense deposit disease) who were treated with antihypertensive medications, dietary protein restriction, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (500",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/49\">",
"     49",
"    </a>",
"    ]. The baseline serum creatinine and protein excretion was similar in both groups (about 1.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [159",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    and 7 to 8",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    respectively). After three years of therapy, protein excretion was significantly lower with antiplatelet therapy (4.3 versus 7.1",
"    <span class=\"nowrap\">",
"     g/day).",
"    </span>",
"    The serum creatinine concentration was stable in both groups.",
"   </p>",
"   <p>",
"    We do",
"    <strong>",
"     not",
"    </strong>",
"    use antiplatelet therapy in patients with MPGN, in part because the above studies were performed prior to our knowledge of the different causes of the disease. (See",
"    <a class=\"local\" href=\"#H56342434\">",
"     'Treatment of the underlying cause'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H205247964\">",
"    <span class=\"h4\">",
"     Anticoagulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early claims of a beneficial effect with the use of anticoagulants (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ) combined with glucocorticoids and cytotoxic agents have not been confirmed by a prospective study and there is potential harm [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/36\">",
"     36",
"    </a>",
"    ]. As an example, two trials in which warfarin was added to antiplatelet therapy demonstrated both conflicting evidence of benefit and a high rate (up to 40 percent) of bleeding complications [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/36,50,51\">",
"     36,50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend",
"    <strong>",
"     not",
"    </strong>",
"    using combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for MPGN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H284123283\">",
"    <span class=\"h3\">",
"     C3 glomerulonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;C3 glomerulonephritis, also called C3 nephropathy, is due to abnormalities in the alternative complement pathway that can lead to an MPGN pattern of injury on renal biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/11,12,52-54\">",
"     11,12,52-54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=see_link&amp;anchor=H455985668#H455985668\">",
"     \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\", section on 'C3 glomerulonephritis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no trials that have evaluated therapy in C3 glomerulonephritis. Patients who have nephrotic range proteinuria or a decreased estimated GFR may be treated according to the cause, if one is identified. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with C3 glomerulonephritis due to autoantibodies to a complement protein may benefit from immunosuppressive therapy (eg, glucocorticoids,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients with a genetic mutation in the complement cascade may benefit from treatment with drugs that inhibit formation of the membrane attack complex (MAC) such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"       eculizumab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/55,56\">",
"       55,56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with elevated serum levels of the membrane attack complex (MAC, which may need to be sent to reference laboratories) may be more likely to respond to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"       eculizumab",
"      </a>",
"      than those with normal serum MAC levels [",
"      <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/55,56\">",
"       55,56",
"      </a>",
"      ]. Patients with MPGN secondary to factor H deficiency may benefit from treatment with plasma infusion [",
"      <a class=\"abstract\" href=\"UTD.htm?13/17/13594/abstract/53,57\">",
"       53,57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H284123290\">",
"    <span class=\"h3\">",
"     Dense deposit disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of dense deposit disease (MPGN type II) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3498?source=see_link&amp;anchor=H15#H15\">",
"     \"Dense deposit disease (membranoproliferative glomerulonephritis type II)\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56342369\">",
"    <span class=\"h1\">",
"     RECURRENT MPGN AFTER RENAL TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with membranoproliferative glomerulonephritis (MPGN) who develop end-stage renal disease undergo renal transplantation. Recurrent MPGN can occur and the management of this disorder is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32614?source=see_link\">",
"     \"Membranoproliferative glomerulonephritis: Recurrence after transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/31/37363?source=see_link\">",
"       \"Patient information: Glomerular disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H284123891\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Membranoproliferative glomerulonephritis (MPGN) is a pattern of glomerular injury viewed by light microscopy. The treatment of MPGN depends upon the underlying cause as most patients have either a circulating immune complex disease or dysregulation of the alternative complement pathway. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immune complex-mediated MPGN is characterized by positive staining for immunoglobulin and complement on immunofluorescence microscopy. Patients who have such findings should be evaluated for infections, autoimmune diseases, and monoclonal gammopathy and, when relevant, appropriate therapy of the underlying disease should be initiated. (See",
"      <a class=\"local\" href=\"#H1655349110\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complement-mediated MPGN is characterized by positive staining for C3 and no staining for immunoglobulin by immunofluorescence microscopy. Such patients should undergo an evaluation for activation of the alternative pathway of complement. (See",
"      <a class=\"local\" href=\"#H1655349110\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As with other glomerular diseases, patients who present with non-nephrotic proteinuria (less than 3.5",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      no hypoalbuminemia, and no edema), normal serum creatinine or estimated glomerular filtration rate, and normal blood pressure have a benign prognosis as long as the renal manifestations do not become more prominent. Poor prognostic signs at presentation include the nephrotic syndrome, an elevated serum creatinine or a reduction in estimated glomerular filtration rate, hypertension, and, on renal biopsy, crescents. (See",
"      <a class=\"local\" href=\"#H56342453\">",
"       'Predictors of renal prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once underlying causes have been excluded, the treatment of idiopathic immune complex-mediated MPGN is determined by the severity of kidney dysfunction. There are limited data to guide therapy. Our approach, which is based upon clinical experience, is as follows (see",
"      <a class=\"local\" href=\"#H267197965\">",
"       'Suggested regimens according to presentation'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who present with non-nephrotic proteinuria (less than 3.5",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      no hypoalbuminemia, and no edema), normal serum creatinine, and normal blood pressure (mild disease), we recommend conservative therapy with angiotensin inhibition alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Regular monitoring of the serum creatinine, urine protein-to-creatinine ratio, and the urinalysis is warranted in such patients to permit detection of disease progression. Although supportive data are not available, patients with more hematuria (eg, 50 or more versus 5 to 20 red blood cells per high power field) may be at greater risk for progressive disease. We suggest that patients with more hematuria be monitored more frequently.",
"     </li>",
"     <li>",
"      For patients who present with nephrotic syndrome and a normal or near normal creatinine, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      in addition to angiotensin inhibition therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Prednisone may be given at a dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (maximum dose 60 to 80",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for 12 to 16 weeks. If the patient responds, prednisone should be tapered to alternate day therapy over six to eight months. If there is less than a 30 percent reduction in proteinuria after 12 to 16 weeks, we suggest tapering and discontinuation of prednisone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Calcineurin inhibitors may be considered in patients who do not respond to or tolerate glucocorticoids.",
"     </li>",
"     <li>",
"      For patients who present with an elevated serum creatinine, with or without nephrotic syndrome",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypertension, and without crescents, we suggest initial therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Prednisone may be given at a dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (maximum dose 60 to 80",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      If there is no response or there are increases in the serum creatinine",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      proteinuria, we suggest adding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We typically use 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, reduced to 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in patients with a serum creatinine greater than 2.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (221",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      or age greater than 60 years for three to six months.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      may be used in patients who do not respond to cyclophosphamide. (See",
"      <a class=\"local\" href=\"#H267200721\">",
"       'Rituximab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with rapidly progressive disease with or without crescents, we recommend that patients be treated with glucocorticoids and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The preferred regimen is described elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18231?source=see_link&amp;anchor=H11#H11\">",
"       \"Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      C3 glomerulonephritis or C3 nephropathy occurs as a result of abnormalities in the alternative complement pathway that can lead to an MPGN pattern of injury on renal biopsy. There are no trials that have evaluated therapy in C3 glomerulonephritis. Patients who have nephrotic range proteinuria or a decreased estimated GFR may be treated according to the cause, if one is identified. (See",
"      <a class=\"local\" href=\"#H284123283\">",
"       'C3 glomerulonephritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H56342434\">",
"       'Treatment of the underlying cause'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of dense deposit disease (MPGN type II) is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3498?source=see_link&amp;anchor=H15#H15\">",
"       \"Dense deposit disease (membranoproliferative glomerulonephritis type II)\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/1\">",
"      Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis--a new look at an old entity. N Engl J Med 2012; 366:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/2\">",
"      Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin Nephrol 2011; 31:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/3\">",
"      Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/4\">",
"      Goules A, Masouridi S, Tzioufas AG, et al. Clinically significant and biopsy-documented renal involvement in primary Sj&ouml;gren syndrome. Medicine (Baltimore) 2000; 79:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/5\">",
"      Cortez MS, Sturgill BC, Bolton WK. Membranoproliferative glomerulonephritis with primary Sj&ouml;gren's syndrome. Am J Kidney Dis 1995; 25:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/6\">",
"      Waldherr R, Seelig HP, Klare B, Abigt J. Membranoproliferative glomerulonephritis in systemic sclerosis of childhood. Virchows Arch A Pathol Anat Histol 1978; 379:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/7\">",
"      Sethi S, Zand L, Leung N, et al. Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Clin J Am Soc Nephrol 2010; 5:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/8\">",
"      Moulin B, Ronco PM, Mougenot B, et al. Glomerulonephritis in chronic lymphocytic leukemia and related B-cell lymphomas. Kidney Int 1992; 42:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/9\">",
"      Nasr SH, Satoskar A, Markowitz GS, et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol 2009; 20:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/10\">",
"      Guiard E, Karras A, Plaisier E, et al. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab. Clin J Am Soc Nephrol 2011; 6:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/11\">",
"      Sethi S, Fervenza FC, Zhang Y, et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int 2012; 82:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/12\">",
"      Servais A, No&euml;l LH, Roumenina LT, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012; 82:454.",
"     </a>",
"    </li>",
"    <li>",
"     Elewa U, Sandri, A.M., Rizza, S.A., Fervenza, F.C. Treatment of Hepatitis B Virus-Associated Nephropathy. Nephron Clin Pract 2011; 119: 41-49",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/14\">",
"      Neugarten J, Baldwin DS. Glomerulonephritis in bacterial endocarditis. Am J Med 1984; 77:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/15\">",
"      Bartel C, Oberm&uuml;ller N, Rummel MJ, et al. Remission of a B cell CLL-associated membranoproliferative glomerulonephritis Type I with rituximab and bendamustine. Clin Nephrol 2008; 69:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/16\">",
"      Bourke E, Campbell WG Jr, Piper M, Check IJ. Hypocomplementemic proliferative glomerulonephritis with C3 nephritic-factor-like activity in multiple myeloma. Nephron 1989; 52:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/17\">",
"      Bennett WM, Fassett RG, Walker RG, et al. Mesangiocapillary glomerulonephritis type II (dense-deposit disease): clinical features of progressive disease. Am J Kidney Dis 1989; 13:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/18\">",
"      Cameron JS, Turner DR, Heaton J, et al. Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am J Med 1983; 74:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/19\">",
"      D'Amico G, Ferrario F. Mesangiocapillary glomerulonephritis. J Am Soc Nephrol 1992; 2:S159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/20\">",
"      Little MA, Dupont P, Campbell E, et al. Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk. Kidney Int 2006; 69:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/21\">",
"      Somers M, Kertesz S, Rosen S, et al. Non-nephrotic children with membranoproliferative glomerulonephritis: are steroids indicated? Pediatr Nephrol 1995; 9:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/22\">",
"      Donadio JV Jr, Offord KP. Reassessment of treatment results in membranoproliferative glomerulonephritis, with emphasis on life-table analysis. Am J Kidney Dis 1989; 14:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/23\">",
"      Schena FP, Cameron JS. Treatment of proteinuric idiopathic glomerulonephritides in adults: a retrospective survey. Am J Med 1988; 85:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/24\">",
"      Alchi B, Jayne D. Membranoproliferative glomerulonephritis. Pediatr Nephrol 2010; 25:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/25\">",
"      Glassock RJ, Bargman JM, Palmer BF, et al. Nephrology Quiz and Questionnaire: 2009. Clin J Am Soc Nephrol 2010; 5:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/26\">",
"      Fervenza FC, Sethi S, Glassock RJ. Idiopathic membranoproliferative glomerulonephritis: does it exist? Nephrol Dial Transplant 2012; 27:4288.",
"     </a>",
"    </li>",
"    <li>",
"     Glassock R. Membranoproliferative glomerulonephritis. In: Glassock CPaR (ed). Treatment of Primary Glomerulonephritis. Oxford Medical Publications: Oxford, 2009, pp 375-398.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/28\">",
"      Tarshish P, Bernstein J, Tobin JN, Edelmann CM Jr. Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone--a report of the International Study of Kidney Disease in Children. Pediatr Nephrol 1992; 6:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/29\">",
"      McEnery PT, McAdams AJ, West CD. The effect of prednisone in a high-dose, alternate-day regimen on the natural history of idiopathic membranoproliferative glomerulonephritis. Medicine (Baltimore) 1985; 64:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/30\">",
"      McEnery PT. Membranoproliferative glomerulonephritis: the Cincinnati experience--cumulative renal survival from 1957 to 1989. J Pediatr 1990; 116:S109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/31\">",
"      Ford DM, Briscoe DM, Shanley PF, Lum GM. Childhood membranoproliferative glomerulonephritis type I: limited steroid therapy. Kidney Int 1992; 41:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/32\">",
"      Braun MC, West CD, Strife CF. Differences between membranoproliferative glomerulonephritis types I and III in long-term response to an alternate-day prednisone regimen. Am J Kidney Dis 1999; 34:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/33\">",
"      Bahat E, Akkaya BK, Akman S, et al. Comparison of pulse and oral steroid in childhood membranoproliferative glomerulonephritis. J Nephrol 2007; 20:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/34\">",
"      Bergstein JM, Andreoli SP. Response of type I membranoproliferative glomerulonephritis to pulse methylprednisolone and alternate-day prednisone therapy. Pediatr Nephrol 1995; 9:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/35\">",
"      Orlowski T, Rancewicz Z, Lao M, et al. Long-term immunosuppressive therapy of idiopathic membranoproliferative glomerulonephritis. Klin Wochenschr 1988; 66:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/36\">",
"      Cattran DC, Cardella CJ, Roscoe JM, et al. Results of a controlled drug trial in membranoproliferative glomerulonephritis. Kidney Int 1985; 27:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/37\">",
"      Faedda R, Satta A, Tanda F, et al. Immunosuppressive treatment of membranoproliferative glomerulonephritis. Nephron 1994; 67:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/38\">",
"      Bhat P, Weiss S, Appel GB, Radhakrishnan J. Rituximab treatment of dysproteinemias affecting the kidney: a review of three cases. Am J Kidney Dis 2007; 50:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/39\">",
"      Vilayur E, Trevillian P, Walsh M. Monoclonal gammopathy and glomerulopathy associated with chronic lymphocytic leukemia. Nat Clin Pract Nephrol 2009; 5:54.",
"     </a>",
"    </li>",
"    <li>",
"     Dillon JJ, Hladunewich M, Haley WE, et al. Rituximab therapy for type I membranoproliferative glomerulonephritis. Clin Nephrol 2012; 77:290.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/41\">",
"      Jones G, Juszczak M, Kingdon E, et al. Treatment of idiopathic membranoproliferative glomerulonephritis with mycophenolate mofetil and steroids. Nephrol Dial Transplant 2004; 19:3160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/42\">",
"      Choi MJ, Eustace JA, Gimenez LF, et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002; 61:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/43\">",
"      Bayazit AK, Noyan A, Cengiz N, Anarat A. Mycophenolate mofetil in children with multidrug-resistant nephrotic syndrome. Clin Nephrol 2004; 61:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/44\">",
"      Bagheri N, Nemati E, Rahbar K, et al. Cyclosporine in the treatment of membranoproliferative glomerulonephritis. Arch Iran Med 2008; 11:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/45\">",
"      Cattran DC. Current status of cyclosporin A in the treatment of membranous, IgA and membranoproliferative glomerulonephritis. Clin Nephrol 1991; 35 Suppl 1:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/46\">",
"      Matsumoto H, Shibasaki T, Ohno I, et al. [Effect of cyclosporin monotherapy on proteinuria in a patient with membranoproliferative glomerulonephritis]. Nihon Jinzo Gakkai Shi 1995; 37:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/47\">",
"      Haddad M, Lau K, Butani L. Remission of membranoproliferative glomerulonephritis type I with the use of tacrolimus. Pediatr Nephrol 2007; 22:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/48\">",
"      Donadio JV Jr, Anderson CF, Mitchell JC 3rd, et al. Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy. N Engl J Med 1984; 310:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/49\">",
"      Z&auml;uner I, B&ouml;hler J, Braun N, et al. Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multicentre prospective clinical trial. Collaborative Glomerulonephritis Therapy Study Group (CGTS). Nephrol Dial Transplant 1994; 9:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/50\">",
"      Zimmerman SW, Moorthy AV, Dreher WH, et al. Prospective trial of warfarin and dipyridamole in patients with membranoproliferative glomerulonephritis. Am J Med 1983; 75:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/51\">",
"      Harmankaya O, Bat&uuml;rk T, Ozt&uuml;rk Y, et al. Effect of acetylsalicylic acid and dipyridamole in primary membranoproliferative glomerulonephritis type I. Int Urol Nephrol 2001; 33:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/52\">",
"      Servais A, Fr&eacute;meaux-Bacchi V, Lequintrec M, et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 2007; 44:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/53\">",
"      Habbig S, Mihatsch MJ, Heinen S, et al. C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int 2009; 75:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/54\">",
"      Fakhouri F, Fr&eacute;meaux-Bacchi V, No&euml;l LH, et al. C3 glomerulopathy: a new classification. Nat Rev Nephrol 2010; 6:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/55\">",
"      Radhakrishnan S, Lunn A, Kirschfink M, et al. Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med 2012; 366:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/56\">",
"      Bomback AS, Smith RJ, Barile GR, et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012; 7:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/17/13594/abstract/57\">",
"      Licht C, Weyersberg A, Heinen S, et al. Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis 2005; 45:415.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3058 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-CF9877BBA9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_17_13594=[""].join("\n");
var outline_f13_17_13594=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H284123891\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H267198035\">",
"      PATHOLOGIC CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1655349110\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20702942\">",
"      Immune complex-mediated MPGN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20702949\">",
"      Complement-mediated MPGN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H56342427\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56342434\">",
"      Treatment of the underlying cause",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56342453\">",
"      Predictors of renal prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H858669072\">",
"      Treatment of the glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H284123153\">",
"      - Idiopathic immune complex-mediated MPGN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H182574437\">",
"      Immunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H267197965\">",
"      - Suggested regimens according to presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H267200713\">",
"      - Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H267200721\">",
"      - Rituximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H20875950\">",
"      - Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H267200942\">",
"      - Calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Antiplatelet agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H205247964\">",
"      Anticoagulants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H284123283\">",
"      - C3 glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H284123290\">",
"      - Dense deposit disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H56342369\">",
"      RECURRENT MPGN AFTER RENAL TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H284123891\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3058\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3058|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/56/11145\" title=\"picture 1A\">",
"      MPGN Light I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/21/20825\" title=\"picture 1B\">",
"      MPGN Light II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/37/8793\" title=\"picture 2\">",
"      Type I MPGN EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/19/24883\" title=\"picture 3\">",
"      Dense deposit disease EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/8/34953\" title=\"picture 4\">",
"      Electron micrograph type 3 MPGN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/12/22727\" title=\"picture 5\">",
"      C3 glomerulonephritis IF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3058|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/63/34812\" title=\"table 1\">",
"      Labs that assay complement",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=related_link\">",
"      Classification and diagnosis of Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4041?source=related_link\">",
"      Clinical course and management of monoclonal gammopathy of undetermined significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=related_link\">",
"      Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3498?source=related_link\">",
"      Dense deposit disease (membranoproliferative glomerulonephritis type II)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=related_link\">",
"      Determination of initial therapy in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27706?source=related_link\">",
"      Diagnosis and classification of renal disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43095?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=related_link\">",
"      Diagnosis of monoclonal gammopathy of undetermined significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32614?source=related_link\">",
"      Membranoproliferative glomerulonephritis: Recurrence after transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18231?source=related_link\">",
"      Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=related_link\">",
"      Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/31/37363?source=related_link\">",
"      Patient information: Glomerular disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44488?source=related_link\">",
"      Renal disease associated with hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=related_link\">",
"      Renal disease associated with hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6362?source=related_link\">",
"      Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37626?source=related_link\">",
"      Treatment and prognosis of Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34714?source=related_link\">",
"      Treatment of primary focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=related_link\">",
"      Treatment of relapsed or refractory chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36682?source=related_link\">",
"      Treatment of the mixed cryoglobulinemia syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_17_13595="Test exfol cells urine";
var content_f13_17_13595=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tests analyzing exfoliated cells",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Target",
"      </td>",
"      <td class=\"subtitle1\">",
"       Assay",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Automated cytology assays",
"      </td>",
"      <td>",
"       Quanticyt",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cytokeratin 20",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Telomerase",
"      </td>",
"      <td>",
"       TRAP",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Telomerase",
"      </td>",
"      <td>",
"       hTERT",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Microsatellite DNA",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chromosomal abnormalities (chromosomes 3, 7, 17, and 9p21)",
"      </td>",
"      <td>",
"       UroVysion*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Carcinoembryonic antigen (CEA), two mucoproteins",
"      </td>",
"      <td>",
"       ImmunoCyt",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nuclear morphology abnormalities",
"      </td>",
"      <td>",
"       Quanticyt",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       DD23",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lewis X antigen",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * United States Food and Drug Administration approved.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_17_13595=[""].join("\n");
var outline_f13_17_13595=null;
var title_f13_17_13596="Aneurysm risk in CN3 palsy";
var content_f13_17_13596=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F76645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F76645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk of aneurysm based on internal and external dysfunction of the third nerve",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Internal and external dysfunction",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk of aneurysm",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommendation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Complete internal dysfunction (\"pupil blown\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        With complete external dysfunction",
"       </td>",
"       <td>",
"        Highest",
"       </td>",
"       <td>",
"        MRI/MRA (CTA) catheter angiogram",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        With incomplete external dysfunction",
"       </td>",
"       <td>",
"        Highest",
"       </td>",
"       <td>",
"        MRI/MRA (CTA) catheter angiogram",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Without external dysfunction",
"       </td>",
"       <td>",
"        Minimal",
"       </td>",
"       <td>",
"        No imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Incomplete internal dysfunction (\"partial pupil\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        With complete external dysfunction",
"       </td>",
"       <td>",
"        Uncertain, probably low",
"       </td>",
"       <td>",
"        MRI/MRA (CTA) consider catheter angiogram",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        With incomplete external dysfunction",
"       </td>",
"       <td>",
"        Uncertain, minimal",
"       </td>",
"       <td>",
"        MRI/MRA (CTA) consider catheter angiogram",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Without external dysfunction",
"       </td>",
"       <td>",
"        Minimal",
"       </td>",
"       <td>",
"        No imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        No internal dysfunction (\"pupil not involved\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        With complete external dysfunction",
"       </td>",
"       <td>",
"        Low if isolated",
"       </td>",
"       <td>",
"        Observe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        With incomplete external dysfunction",
"       </td>",
"       <td>",
"        Uncertain",
"       </td>",
"       <td>",
"        MRI/MRA (CTA) consider catheter angiogram",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MRA: magnetic resonance angiography; MRI: magnetic resonance imaging; CTA: computed tomography angiography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_17_13596=[""].join("\n");
var outline_f13_17_13596=null;
var title_f13_17_13597="Effect of blood flow on urea clearance during hemodialysis";
var content_f13_17_13597=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F55473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F55473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Figure showing the effect of blood flow on urea clearance during hemodialysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 426px; height: 280px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The effect of increasing dialyzer blood flow (Qb) on urea clearance (Kd) in hemodialysis for a given KoA approximately 1000. Increasing flow raises Kd by delivering more blood with a high urea concentration, thereby maintaining a favorable concentration gradient for urea diffusion across the dialysis membrane. There is a relative plateau above 500 mL/min due to limitations of the dialysis membrane. A similar relationship is seen between dialysate flow and Kd; in this setting, the concentration gradient is maintained as dialysate flow rises by the supply of new dialysate containing no urea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_17_13597=[""].join("\n");
var outline_f13_17_13597=null;
var title_f13_17_13598="Efficacy of amiodarone and flecainide in AF";
var content_f13_17_13598=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Efficacy of amiodarone in rate control for atrial fibrillation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 281px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of intravenous placebo, amiodarone, and flecainide on the ventricular response to atrial fibrillation in patients who failed to revert to sinus rhythm after the initiation of therapy. Amiodarone slowed the ventricular response, an effect that was not seen with flecainide or placebo. Although flecainide was less effective for rate control, it was associated with earlier reversion to sinus rhythm than amiodarone or placebo. Note that the time scale is nonlinear.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Donovan KD, Power BM, Hockings GE, et al. Am J Cardiol 1995; 75:693.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_17_13598=[""].join("\n");
var outline_f13_17_13598=null;
var title_f13_17_13599="Management of unanticipated difficult airway in pregnant women";
var content_f13_17_13599=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Management of unanticipated difficult airway in pregnant women",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 536px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LMA: laryngeal mask airway; ILMA: intubating laryngeal mask airway; TTJV: transtracheal jet ventilation.",
"     <br>",
"      * Optimize positioning. Try a different laryngoscope, bougie, stylet, and/or provider.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_17_13599=[""].join("\n");
var outline_f13_17_13599=null;
